1
|
Schneckenburger R, Boulanger M, Nehme A, Watrin M, Le Du G, Guettier S, Guittet L, Touzé E. Epidemiology of transient ischemic attack in the normandy stroke population-based study. Eur Stroke J 2024:23969873241251722. [PMID: 38711259 DOI: 10.1177/23969873241251722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2024] Open
Abstract
INTRODUCTION Transient ischemic attack (TIA) is a frequent neurological emergency which management and definition have changed radically over the last 15 years. However, recent epidemiological studies of TIA are scarce. We report here on the impact of the shift from a time-based to a tissue-based definition of TIA on its incidence and risk of recurrence in a new population-based cohort with a high rate of patients investigated by MRI. MATERIALS AND METHODS We prospectively included all TIAs that occurred between May 2017 and May 2021 from the Normandy Stroke Study, a population-based registry using multiple overlapping sources for exhaustive case identification in Caen la Mer area. TIAs were classified as either time-based (symptoms <24 h) or tissue-based (<24 h and no lesion on brain imaging). Attack and incidence rates were calculated, as was the 90-day ischemic stroke rate. RESULTS Five hundred and sixty-seven TIAs (549 single patients) were included, with 80.6% having a brain MRI. Four hundred and ten (72.3%) met the definition of tissue-based TIA. The age standardized attack (to the 2013 European population) rate was 39.5 (95% CI 35.7-43.5) and the age-standardized incidence rate (first ever cerebrovascular event) was 29.7 (95% CI 27.3-34.2). The overall recurrent stroke rate at 90 days was 2.7%, with no difference between patients with or without ischemic lesions on MRI. CONCLUSION We found that the use of the tissue-based definition of TIA resulted in a 27.5% reduction in incidence as compared to the time-based definition, but had no impact on the 90-day stroke rate. The burden of TIA remains high, and is likely to increase as the population ages.
Collapse
Affiliation(s)
- Romain Schneckenburger
- Université Caen Normandie, Caen, France
- Department of Neurology, CHU de Caen Normandie, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| | - Marion Boulanger
- Université Caen Normandie, Caen, France
- Department of Neurology, CHU de Caen Normandie, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| | - Ahmad Nehme
- Université Caen Normandie, Caen, France
- Department of Neurology, CHU de Caen Normandie, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| | - Marguerite Watrin
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
- Department of Clinical Research, CHU de Caen Normandie, Caen, France
| | - Gwendoline Le Du
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
- Department of Clinical Research, CHU de Caen Normandie, Caen, France
| | - Sophie Guettier
- Department of Neurology, CHU de Caen Normandie, Caen, France
| | - Lydia Guittet
- Université Caen Normandie, Caen, France
- Department of Clinical Research, CHU de Caen Normandie, Caen, France
| | - Emmanuel Touzé
- Université Caen Normandie, Caen, France
- Department of Neurology, CHU de Caen Normandie, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| |
Collapse
|
2
|
Evenden P, Vandoolaeghe Q, Lecluse Y, Gac AC, Delépée R, Weiswald LB, Boutet-Robinet E, Boulanger M, Bonassi S, Lebailly P, Meryet-Figuière M. Agricultural exposures and DNA damage in PBMC of female farmers measured using the alkaline comet assay. Int Arch Occup Environ Health 2024; 97:353-363. [PMID: 38430240 PMCID: PMC10999382 DOI: 10.1007/s00420-024-02049-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/22/2024] [Indexed: 03/03/2024]
Abstract
OBJECTIVE Several studies investigated the link between agricultural occupational exposures and DNA damage, in an attempt to bring elements of biological plausibility to the increased cancer risk associated with them. However, only a few of these studies focused on females. METHODS The comet assay was performed on PBMC (Peripheral Blood Mononuclear Cells) samples from 245 females working in open field farming and cattle raising, located in the Normandy area of France. Individual questionnaires on tasks performed were administered at the time of sampling to directly assess exposures. Environmental exposures were issued from a questionnaire assessing the farm productions. Linear regression analyses were done using the DNA damage scores. RESULTS Regarding direct exposures, several tasks associated with exposure to potentially harmful chemicals were not associated with DNA damage, but a longer duration of use of herbicide on meadows (p = 0.05) or of cleaning and upkeep of agricultural equipment (p = 0.06) revealed higher DNA damage levels, although the number of exposed women was low. Several indirect and/or environmental exposures were associated with DNA damage in multivariate analyses: a larger surface of meadows (p = 0.006) or the presence of poultry (p = 0.03) was associated with less DNA damage, while the presence of swine (p = 0.01) was associated with higher DNA damage. Smokers and former smokers had less DNA damage than non-smokers (p = 0.0008 and p = 0.03). CONCLUSIONS We report modified levels of DNA damage for those environmentally exposed to meadows, poultry and pig farming, underlining the need for a better knowledge of the potential health risks experienced by females in this setting.
Collapse
Affiliation(s)
- P Evenden
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Q Vandoolaeghe
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Y Lecluse
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - A C Gac
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - R Delépée
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - L B Weiswald
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - E Boutet-Robinet
- Toxalim (Research Centre in Food Toxicology), INRAE, ENVT, INP-Purpan, UPS, Université de Toulouse, Toulouse, France
| | - M Boulanger
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - S Bonassi
- Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy
- Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy
| | - P Lebailly
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - M Meryet-Figuière
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France.
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France.
| |
Collapse
|
3
|
de Graaf L, Bresson M, Boulanger M, Bureau M, Lecluse Y, Lebailly P, Baldi I. Pesticide exposure in greenspaces: Comparing field measurement of dermal contamination with values predicted by registration models. Sci Total Environ 2024; 919:170816. [PMID: 38346656 DOI: 10.1016/j.scitotenv.2024.170816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Revised: 02/02/2024] [Accepted: 02/06/2024] [Indexed: 02/17/2024]
Abstract
Since 2014, the Agricultural Operator Exposure Model (AOEM) has been the harmonised European model used for estimating non-dietary operator exposure to pesticide. It is based on studies conducted by the pesticide companies and it features 13 different crops including non-agricultural areas such as amenity grasslands. The objective of this study was to compare the dermal exposure measured during a field study conducted in a non-agricultural area with the corresponding values estimated by the model AOEM. The non-controlled field study was conducted in France in 2011 and included 24 private and public gardeners who apply glyphosate with knapsack sprayers. Dermal exposure was measured using the whole-body method and cotton gloves. Each measured value had an estimated value given by AOEM and we tested their correlation using linear regression. The model overestimated body exposure for all observations and there was no correlation between values. However, it underestimated hand exposure by 42 times and it systematically underestimated the exposure when the operators were wearing gloves, especially during the application. The model failed at being conservative regarding hand exposure and highly overestimated the protection afforded by the gloves. At a time of glyphosate renewed approval in Europe, non-controlled field studies conducted by academics are needed to improve AOEM model, especially in the non-agricultural sector. Indeed, among the 34 studies included in the model, none were conducted on a non-agricultural area and only four assessed the exposure when using a knapsack sprayer. Moreover, knapsack sprayers being the main equipment used worldwide in both agricultural and non-agricultural settings, it is also crucial to integrate new data specific to this equipment in the model. Operator exposure should be estimated with accuracy in the registration process of pesticides to ensure proper safety as well as in epidemiological studies to improve exposure assessment.
Collapse
Affiliation(s)
- L de Graaf
- Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France.
| | - M Bresson
- INSERM, UMR1086-Cancers et Préventions, Centre François Baclesse, Caen, France; University Caen Normandie, Caen, France
| | - M Boulanger
- INSERM, UMR1086-Cancers et Préventions, Centre François Baclesse, Caen, France; University Caen Normandie, Caen, France
| | - M Bureau
- Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France
| | - Y Lecluse
- INSERM, UMR1086-Cancers et Préventions, Centre François Baclesse, Caen, France
| | - P Lebailly
- INSERM, UMR1086-Cancers et Préventions, Centre François Baclesse, Caen, France; University Caen Normandie, Caen, France
| | - I Baldi
- Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France; Service Santé Travail Environnement, CHU de Bordeaux, F-33000 Bordeaux, France
| |
Collapse
|
4
|
Clarençon F, Durand-Zaleski I, Premat K, Baptiste A, Chabert E, Ferrier A, Labeyrie MA, Reiner P, Spelle L, Denier C, Tuilier T, Hosseini H, Rodriguez-Régent C, Turc G, Fauché C, Lamy M, Lapergue B, Consoli A, Barbier C, Boulanger M, Bricout N, Henon H, Gory B, Richard S, Rouchaud A, Macian-Montoro F, Eker O, Cho TH, Soize S, Moulin S, Gentric JC, Timsit S, Darcourt J, Albucher JF, Janot K, Annan M, Pico F, Costalat V, Arquizan C, Marnat G, Sibon I, Pop R, Wolff V, Shotar E, Lenck S, Sourour NA, Radenne A, Alamowitch S, Dechartres A. Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion: A randomized controlled trial. Int J Stroke 2024; 19:367-372. [PMID: 37740419 DOI: 10.1177/17474930231205213] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/24/2023]
Abstract
RATIONALE Mechanical thrombectomy (MT) associated with the best medical treatment (BMT) has recently shown efficacy for the management of acute ischemic stroke (AIS) secondary to a large vessel occlusion. However, evidence is lacking regarding the benefit of MT for more distal occlusions. AIM To evaluate the efficacy in terms of good clinical outcome at 3 months of MT associated with the BMT over the BMT alone in AIS related to a distal occlusion. METHODS The DISCOUNT trial is a multicenter open-label randomized controlled trial involving French University hospitals. Adult patients (⩾18 years) with an AIS involving the anterior or posterior circulation secondary to a distal vessel occlusion within 6 h of symptom onset or within 24 h if no hyperintense signal on fluid attenuation inversion recovery acquisition will be randomized 1:1 to receive either MT associated with the BMT (experimental group) or BMT alone (control group). The number of patients to be included is 488. STUDY OUTCOMES The primary outcome is the rate of good clinical outcome at 3 months defined as a modified Rankin scale (mRS) ⩽2 and evaluated by an independent assessor blinded to the intervention arm. Secondary outcomes include recanalization of the occluded vessel within 48 h, angiographic reperfusion in the experimental group, 3-month excellent clinical outcome (mRS ⩽ 1), all adverse events, and death. A cost utility analysis will estimate the incremental cost per quality-adjusted life year (QALY) gained. DISCUSSION If positive, this study will open new insights in the management of AISs. TRIAL REGISTRATION ClinicalTrials.gov: NCT05030142 registered on 1 September 2021.
Collapse
Affiliation(s)
- Frédéric Clarençon
- Sorbonne Université, GRC BioFast, APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Isabelle Durand-Zaleski
- Université de Paris, CRESS, INSERM, INRA, URCEco, AP-HP, Hôpital de l'Hôtel Dieu, Paris, France
| | - Kévin Premat
- APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Amandine Baptiste
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Unité de recherche clinique, Paris, France
| | - Emmanuel Chabert
- Department of Neuroradiology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Anna Ferrier
- Department of Vascular Neurology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | | | - Peggy Reiner
- Department of Vascular Neurology, Lariboisière Hospital, Paris, France
| | - Laurent Spelle
- Department of Interventional Neuroradiology, Kremlin-Bicêtre Hospital, Kremlin-Bicêtre, France
| | - Christian Denier
- Department of Vascular Neurology, Kremlin-Bicêtre Hospital, Kremlin-Bicêtre, France
| | - Titien Tuilier
- Department of Neuroradiology, Henri-Mondor Hospital, Créteil, France
| | - Hassan Hosseini
- Department of Vascular Neurology, Henri-Mondor Hospital, Créteil, France
| | | | - Guillaume Turc
- Department of Vascular Neurology, Sainte-Anne Hospital, Paris, France
| | - Cédric Fauché
- Department of Neuroradiology, Poitiers University Hospital, Poitiers, France
| | - Matthias Lamy
- Department of Vascular Neurology, Poitiers University Hospital, Poitiers, France
| | | | - Arturo Consoli
- Department of Neuroradiology, Foch Hospital, Suresnes, France
| | - Charlotte Barbier
- Department of Neuroradiology, Caen University Hospital, Caen, France
| | - Marion Boulanger
- Department of Vascular Neurology, Caen University Hospital, Caen, France
| | - Nicolas Bricout
- Department of Neuroradiology, Lille University Hospital, Lille, France
| | - Hilde Henon
- Department of Vascular Neurology, Lille University Hospital, Lille, France
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology, INSERM U1254, CHRU-Nancy, Université de Lorraine, Nancy, France
| | - Sébastien Richard
- Department of Neurology, INSERM U1116, Stroke Unit, CHRU-Nancy, Université de Lorraine, Nancy, France
| | - Aymeric Rouchaud
- Department of Interventional Neuroradiology, Limoges University Hospital, Limoges, France
| | | | - Omer Eker
- Department of Neuroradiology, Lyon University Hospital, Lyon, France
| | - Tae-Hee Cho
- Department of Vascular Neurology, Lyon University Hospital, Lyon, France
| | - Sébastien Soize
- Department of Neuroradiology, Reims University Hospital, Reims, France
| | - Solène Moulin
- Department of Vascular Neurology, Reims University Hospital, Reims, France
| | | | - Serge Timsit
- Department of Vascular Neurology, Brest University Hospital, Brest, France
| | - Jean Darcourt
- Department of Neuroradiology, Toulouse University Hospital, Toulouse, France
| | | | - Kévin Janot
- Department of Neuroradiology, Tours University Hospital, Tours, France
| | - Mariam Annan
- Department of Vascular Neurology, Tours University Hospital, Tours, France
| | - Fernando Pico
- Department of Vascular Neurology, Versailles Hospital, Versailles, France
| | - Vincent Costalat
- Department of Neuroradiology, Montpellier University Hospital, Montpellier, France
| | - Caroline Arquizan
- Department of Vascular Neurology, Montpellier University Hospital, Montpellier, France
| | - Gautier Marnat
- Department of Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | - Igor Sibon
- Department of Vascular Neurology, Bordeaux University Hospital, Bordeaux, France
| | - Raoul Pop
- Department of Neuroradiology, Strasbourg University Hospital, Strasbourg, France
| | - Valérie Wolff
- Department of Vascular Neurology, Strasbourg University Hospital, Strasbourg, France
| | - Eimad Shotar
- Sorbonne Université, GRC BioFast, APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphanie Lenck
- Sorbonne Université, GRC BioFast, APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Nader-Antoine Sourour
- Sorbonne Université, GRC BioFast, APHP, Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Anne Radenne
- AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Unité de recherche clinique, Paris, France
| | - Sonia Alamowitch
- Department of Vascular Neurology, Pitié-Salpêtrière Hospital, Paris, France
| | - Agnès Dechartres
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Paris, France
| |
Collapse
|
5
|
Pop R, Räty S, Riva R, Marnat G, Dobrocky T, Alexandre PL, Lefebvre M, Albucher JF, Boulanger M, Di Maria F, Richard S, Soize S, Piechowiak EI, Liman J, Reich A, Ribo M, Meinel T, Mpotsaris A, Liebeskind DS, Gralla J, Fischer U, Kaesmacher J. Effect of Bridging Thrombolysis on the Efficacy of Stent Retriever Thrombectomy Techniques : Insights from the SWIFT-DIRECT trial. Clin Neuroradiol 2024; 34:93-103. [PMID: 37640839 DOI: 10.1007/s00062-023-01340-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 07/11/2023] [Indexed: 08/31/2023]
Abstract
BACKGROUND There are little available data regarding the influence of intravenous thrombolysis (IVT) on the efficacy of different first line endovascular treatment (EVT) techniques. METHODS We used the dataset of the SWIFT-DIRECT trial which randomized 408 patients to IVT + EVT or EVT alone at 48 international sites. The protocol required the use of a stent retriever (SR), but concomitant use of a balloon guide catheter (BGC) and/or distal aspiration (DA) catheter was left to the discretion of the operators. Four first line techniques were applied in the study population: SR, SR + BGC, SR + DA, SR + DA + BGC. To assess whether the effect of allocation to IVT + EVT versus EVT alone was modified by the first line technique, interaction models were fitted for predefined outcomes. The primary outcome was first pass mTICI 2c‑3 reperfusion (FPR). RESULTS This study included 385 patients of whom 172 were treated with SR + DA, 121 with SR + DA + BGC, 57 with SR + BGC and 35 with SR. There was no evidence that the effect of IVT + EVT versus EVT alone would be modified by the choice of first line technique; however, allocation to IVT + EVT increased the odds of FPR by a factor of 1.68 (95% confidence interval, CI 1.11-2.54). CONCLUSION This post hoc analysis does not suggest treatment effect heterogeneity of IVT + EVT vs EVT alone in different stent retriever techniques but provides evidence for increased FPR if bridging IVT is administered before stent retriever thrombectomy.
Collapse
Affiliation(s)
- Raoul Pop
- Interventional Neuroradiology Department, Strasbourg University Hospitals, Strasbourg, France.
- INSERM U1255, University of Strasbourg, Strasbourg, France.
- Institut de Chirurgie Minime Invasive Guidée par l'Image, Strasbourg, France.
| | - Silja Räty
- Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Roberto Riva
- Department of Neuroradiology, Hospices Civils de Lyon, Lyon, France
| | - Gaultier Marnat
- Department of Interventional and Diagnostic Neuroradiology, CHU Bordeaux, University of Bordeaux, Bordeaux, France
| | - Tomas Dobrocky
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Pierre Louis Alexandre
- Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | | | | | - Marion Boulanger
- Service de Neurologie, Université Caen Normandie, CHU Caen Normandie, Caen, France
| | - Federico Di Maria
- Department of Stroke and Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Sébastien Richard
- Department of Neurology, Stroke Unit, CHRU-Nancy, INSERM U1116, Université de Lorraine, Nancy, France
| | | | - Eike Immo Piechowiak
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Jan Liman
- Department of Neurology, University Medical Center Goettingen, Goettingen, Germany
- Department of Neurology, University Medical Center Nuremberg, Paracelsus Private University, Nuremberg, Germany
| | - Arno Reich
- Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany
| | - Marc Ribo
- Stroke Unit. Department of Neurology, Vall d'Hebron Hospital, Barcelona, Spain
| | - Thomas Meinel
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | | | - David S Liebeskind
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, USA
| | - Jan Gralla
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Urs Fischer
- Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Johannes Kaesmacher
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| |
Collapse
|
6
|
Boisseau W, Benomar A, Ducroux C, Fahed R, Smajda S, Diestro JDB, Charbonnier G, Ognard J, Burel J, Ter Schiphorst A, Boulanger M, Nehme A, Boucherit J, Marnat G, Volders D, Holay Q, Forestier G, Bretzner M, Roy D, Vingadassalom S, Elhorany M, Nico L, Jacquin G, Abdalkader M, Guedon A, Seners P, Janot K, Dumas V, Olatunji R, Gazzola S, Milot G, Zehr J, Darsaut TE, Iancu D, Raymond J. The Management of Persistent Distal Occlusions after Mechanical Thrombectomy and Thrombolysis: An Inter- and Intrarater Agreement Study. AJNR Am J Neuroradiol 2024:ajnr.A8149. [PMID: 38388684 DOI: 10.3174/ajnr.a8149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 10/24/2023] [Indexed: 02/24/2024]
Abstract
BACKGROUND AND PURPOSE The best management of patients with persistent distal occlusion after mechanical thrombectomy with or without IV thrombolysis remains unknown. We sought to evaluate the variability and agreement in decision-making for persistent distal occlusions. MATERIALS AND METHODS A portfolio of 60 cases was sent to clinicians with varying backgrounds and experience. Responders were asked whether they considered conservative management or rescue therapy (stent retriever, aspiration, or intra-arterial thrombolytics) a treatment option as well as their willingness to enroll patients in a randomized trial. Agreement was assessed using κ statistics. RESULTS The electronic survey was answered by 31 physicians (8 vascular neurologists and 23 interventional neuroradiologists). Decisions for rescue therapies were more frequent (n = 1116/1860, 60%) than for conservative management (n = 744/1860, 40%; P < .001). Interrater agreement regarding the final management decision was "slight" (κ = 0.12; 95% CI, 0.09-0.14) and did not improve when subgroups of clinicians were studied according to background, experience, and specialty or when cases were grouped according to the level of occlusion. On delayed re-questioning, 23 of 29 respondents (79.3%) disagreed with themselves on at least 20% of cases. Respondents were willing to offer trial participation in 1295 of 1860 (69.6%) cases. CONCLUSIONS Individuals did not agree regarding the best management of patients with persistent distal occlusion after mechanical thrombectomy and IV thrombolysis. There is sufficient uncertainty to justify a dedicated randomized trial.
Collapse
Affiliation(s)
- W Boisseau
- From the Department of Interventional Neuroradiology (W.B., S.S.), Fondation Rothschild Hospital, Paris, France
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| | - A Benomar
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| | - C Ducroux
- Department of Neurology (C.D., R.F.), Ottawa Hospital Research Institute & University of Ottawa, Ottawa, Canada
| | - R Fahed
- Department of Neurology (C.D., R.F.), Ottawa Hospital Research Institute & University of Ottawa, Ottawa, Canada
| | - S Smajda
- From the Department of Interventional Neuroradiology (W.B., S.S.), Fondation Rothschild Hospital, Paris, France
| | - J D B Diestro
- Division of Diagnostic and Therapeutic Neuroradiology (J.D.B.D., R.O.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - G Charbonnier
- Interventional Neuroradiology Department (G.C.), Besançon University Hospital, Besançon, France
| | - J Ognard
- Interventional Neuroradiology Department (J.O.), Hôpital de la Cavale Blanche, Brest, Bretagne, France
| | - J Burel
- Department of Radiology (J. Burel), Rouen University Hospital, Rouen, France
| | - A Ter Schiphorst
- Neurology Department (A.T.S.), CHRU Gui de Chauliac, Montpellier, France
| | - M Boulanger
- Department of Neurology (M. Boulanger, A.N.), Caen University Hospital, Caen, France
| | - A Nehme
- Department of Neurology (M. Boulanger, A.N.), Caen University Hospital, Caen, France
| | - J Boucherit
- Department of Radiology (J. Boucherit), Rennes University Hospital, Rennes, France
| | - G Marnat
- Department of Neuroradiology (G. Marnat), University Hospital of Bordeaux, Bordeaux, France
| | - D Volders
- From the Department of Interventional Neuroradiology (W.B., S.S.), Fondation Rothschild Hospital, Paris, France
| | - Q Holay
- Radiology Department (Q.H.), Hôpital d'Instruction des armées Saint-Anne, Toulon, France
| | - G Forestier
- Neuroradiology Department (G.F.), University Hospital of Limoges, Limoges, France
| | - M Bretzner
- Neuroradiology Department (M. Bretzner), CHU Lille, University Lille, Inserm, U1172 Lille Neuroscience & Cognition, F-59000, Lille, France
| | - D Roy
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| | - S Vingadassalom
- Interventional Neuroradiology Department (S.V.), CHRU Marseille, La Timone, France
| | - M Elhorany
- Department of Neuroradiology (M.E.), Groupe Hospitalier de Pitié Salpêtrière, Paris, France
- Department of Neurology (M.E.), Tanta University, Tanta, Egypt
| | - L Nico
- Department of Radiology (L.N.), University Hospital of Padova, Padova, Italy
| | - G Jacquin
- Neurovascular Health Program (G.J.), Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
| | - M Abdalkader
- Department of Radiology (M.A.), Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
| | - A Guedon
- Department of Neuroradiology (A.G.), Lariboisière Hospital, Paris, France
| | - P Seners
- Neurology Department (P.S.), Hôpital Fondation A. de Rothschild, Fondation Rothschild Hospital, Paris, France
- Institut de Psychiatrie et Neurosciences de Paris (P.S.), UMR_S1266, INSERM, Université de Paris, Paris, France
| | - K Janot
- Interventional Neuroradiology (K.J.), University Hospital of Tours, Tours, France
| | - V Dumas
- Radiology Department (V.D.), University Hospital of Poitiers, Poitiers, France
| | - R Olatunji
- Division of Diagnostic and Therapeutic Neuroradiology (J.D.B.D., R.O.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - S Gazzola
- From the Department of Interventional Neuroradiology (W.B., S.S.), Fondation Rothschild Hospital, Paris, France
- From the Department of Interventional Neuroradiology (W.B., S.S.), Fondation Rothschild Hospital, Paris, France
| | - G Milot
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| | - J Zehr
- Department of Neurology (C.D., R.F.), Ottawa Hospital Research Institute & University of Ottawa, Ottawa, Canada
- Department of Neurology (C.D., R.F.), Ottawa Hospital Research Institute & University of Ottawa, Ottawa, Canada
| | - T E Darsaut
- Division of Diagnostic and Therapeutic Neuroradiology (J.D.B.D., R.O.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
- Division of Diagnostic and Therapeutic Neuroradiology (J.D.B.D., R.O.), Department of Medical Imaging, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - D Iancu
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| | - J Raymond
- Department of Radiology (W.B., A.B., D.R, D.I., J.R.), Centre Hospitalier de l'Université de Montréal Montréal, Canada
| |
Collapse
|
7
|
Yaghi S, Shu L, Mandel DM, Leon Guerrero CR, Henninger N, Muppa J, Affan M, Ul Haq Lodhi O, Heldner MR, Antonenko K, Seiffge DJ, Arnold M, Salehi Omran S, Crandall RC, Lester E, Lopez Mena D, Arauz A, Nehme A, Boulanger M, Touzé E, Sousa JA, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito MTÁP, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann J, Engelter ST, Traenka C, Aguiar de Sousa D, Soares M, Rosa SD, Zhou LW, Gandhi P, Field TS, Mancini S, Metanis I, Leker RR, Pan K, Dantu V, Baumgartner KV, Burton TM, Freiin von Rennenberg R, Nolte CH, Choi RK, MacDonald JA, Bavarsad Shahripour R, Guo X, Ghannam M, AlMajali M, Samaniego EA, Sanchez S, Rioux B, Zine-Eddine F, Poppe AY, Fonseca AC, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin KJ, Kuohn L, Frontera JA, Amar J, Giles JA, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind DS, Molaie AM, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski KP, Eltatawy AR, Chervak LM, Chulluncuy-Rivas R, Aziz YN, Bakradze E, Tran TL, Rodrigo-Gisbert M, Requena M, Saleh Velez FG, Ortiz Garcia JG, Muddasani V, de Havenon A, Vishnu VY, Yaddanapudi SS, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler JE, Mayer SV, Willey JZ, Zubair AS, Cheng YK, Sharma R, Marto JP, Mendes Ferreira V, Klein P, Nguyen TN, Asad SD, Sarwat Z, Balabhadra A, Patel S, Secchi TL, Martins SC, Mantovani GP, Kim YD, Krishnaiah B, Elangovan C, Lingam S, Qureshi AY, Fridman S, Alvarado-Bolaños A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris-Piperas V, Martínez-Marino M, Carrasco Wall VA, Indraswari F, El Jamal S, Liu S, Alvi M, Ali F, Sarvath MM, Morsi RZ, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Simpkins AN, Gomez R, Sen S, Ghani MR, Elnazeir M, Xiao H, Kala NS, Khan F, Stretz C, Mohammadzadeh N, Goldstein ED, Furie KL. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke 2024. [PMID: 38335240 DOI: 10.1161/strokeaha.123.045731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2024]
Abstract
Background: Small, randomized trials of cervical artery dissection (CAD) patients showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with CAD treated with antiplatelets versus anticoagulation. Methods: This is a multi-center observational retrospective international study (16 countries, 63 sites) that included CAD patients without major trauma. The exposure was antithrombotic treatment type (anticoagulation vs. antiplatelets) and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with Inverse Probability of Treatment Weighting (IPTW) to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an "as treated" cross-over approach and only included outcomes occurring on the above treatments. Results: The study included 3,636 patients [402 (11.1%) received exclusively anticoagulation and 2,453 (67.5%) received exclusively antiplatelets]. By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with IPTW, compared to antiplatelet therapy, anticoagulation was associated with a non-significantly lower risk of subsequent ischemic stroke by day 30 (adjusted HR 0.71 95% CI 0.45-1.12, p=0.145) and by day 180 (adjusted HR 0.80 95% CI 0.28-2.24, p=0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR 1.39 95% CI 0.35-5.45, p=0.637) but was by day 180 (adjusted HR 5.56 95% CI 1.53-20.13, p=0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR 0.40 95% CI 0.18-0.88) (Pinteraction=0.009). Conclusions: Our study does not rule out a benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Collapse
Affiliation(s)
- Shadi Yaghi
- Neurology, Alpert Medical School at Brown University, UNITED STATES
| | - Liqi Shu
- Neurology, Alpert Medical School of Brown University, UNITED STATES
| | - Daniel M Mandel
- Neurology, University of Miami Miller School of Medicine, UNITED STATES
| | | | - Nils Henninger
- Departments of Neurology and Psychiatry, University of Massachusetts Medical School, UNITED STATES
| | | | | | | | - Mirjam R Heldner
- Department of Neurology, Inselspital, University Hospital and University of Bern, SWITZERLAND
| | - Kateryna Antonenko
- Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland, SWITZERLAND
| | - David J Seiffge
- Neurology, Inselspital, Bern University Hospital, University of Bern, SWITZERLAND
| | - Marcel Arnold
- Department of Neurology, University hospital of Bern, SWITZERLAND
| | | | | | | | - Diego Lopez Mena
- National Institute of Neurology and Neurosurgery of Mexico, MEXICO
| | - Antonio Arauz
- stroke clinic, Instituto Nacional de Neurologia, MEXICO
| | | | - Marion Boulanger
- Service de neurologie,, Universite Caen Normandie, CHU Caen Normandie, INSERM U1237, CYCERON, boulevard Henri Becquerel, Caen, France, Blood and Brain @ Caen-Normandie Institute (BB@C), Caen, France, FRANCE
| | | | | | | | | | | | | | - Muhib Khan
- Department of Neurology, Mayo Clinic, UNITED STATES
| | | | - Aaron Rothstein
- Department of Neurology, University of Pennsylvania, UNITED STATES
| | - Ossama Khazaal
- Department of Neurology, University of Pennsylvania, UNITED STATES
| | | | | | - Christopher Traenka
- Department of Neurology and Stroke Center, University Hospital Basel, SWITZERLAND
| | | | - Mafalda Soares
- Lisbon Central University Hospital, University of Lisbon, PORTUGAL
| | - Sara Db Rosa
- Neuroradiology, Lisbon Central University Hospital, PORTUGAL
| | - Lily W Zhou
- Neurology, The University of British Columbia, CANADA
| | | | - Thalia S Field
- Centre for Brain Health, Division of Neurology, Vancouver Stroke Program, University of British Columbia, CANADA
| | | | - Issa Metanis
- Hebrew University-Hadassah Medical Center, ISRAEL
| | - Ronen R Leker
- Neurology, Hadassah-Hebrew University Medical Center, ISRAEL
| | - Kelly Pan
- Rhode Island Hospital, UNITED STATES
| | - Vishnu Dantu
- Barrow Neurological Institute - St. Joseph's Hospital and Medical Center, UNITED STATES
| | | | - Tina M Burton
- Neurology, The Warren Alpert Medical School of Brown University, UNITED STATES
| | - Regina Freiin von Rennenberg
- Department of Neurology (Klinik und Hochschulambulanz für Neurologie), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
| | | | | | | | - Reza Bavarsad Shahripour
- University of California San Diego Comprehensive Stroke Center, Department of Neurosciences, University of California, San Diego, USA., UNITED STATES
| | - Xiaofan Guo
- Neurology, Department of Neurology, Loma Linda University Health, UNITED STATES
| | - Malik Ghannam
- Neurology, University of Iowa Hospitals and Clinics, UNITED STATES
| | | | - Edgar A Samaniego
- Neurology, Neurosurgery & Radiology, University of Iowa, UNITED STATES
| | | | | | | | | | - Ana Catarina Fonseca
- Department of Neurosciences and Mental Health (Neurology), University of Lisbon, PORTUGAL
| | - Maria Baptista
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto
| | - Diana Cruz
- Neurology, Hospital Santa Maria - CHULN, PORTUGAL
| | | | - Giovanna De Marco
- Neurology and Stroke Unit, Department of Neuroscience,, Bufalini Hospital, ITALY
| | | | | | | | - Lindsey Kuohn
- Department of Neurology, NYU Langone Health, UNITED STATES
| | | | - Jordan Amar
- Keck School of Medicine of the University of Southern California, UNITED STATES
| | - James A Giles
- Neurology, Yale University School of Medicine, UNITED STATES
| | - Marialuisa Zedde
- Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia
| | | | - Ilaria Grisendi
- Neuromotor physiology, Azienda USL-IRCCS di Reggio Emilia, ITALY
| | - Hipólito Nzwalo
- Ageing and Cerebrovascular Research Group, Algarve Biomedical Research Institute, PORTUGAL
| | - David S Liebeskind
- Neurovascular Imaging Research Core & Neurology, University of California, Los Angeles, UNITED STATES
| | - Amir M Molaie
- Neurology, University of California at Los Angeles Medical Center, UNITED STATES
| | - Annie Cavalier
- Neurology, Duke University School of Medicine, UNITED STATES
| | - Wayneho Kam
- Duke University Hospital; UNC Health Rex Comprehensive Stroke Center, UNITED STATES
| | - Brian Mac Grory
- Neurology, Duke University School of Medicine, UNITED STATES
| | - Sami Al Kasab
- Neurosurgery and Neurology, Medical University of south Carolina, UNITED STATES
| | - Mohammad Anadani
- Neurology, Medical University of South Carolina, College of Medicine, UNITED STATES
| | | | | | - Lina M Chervak
- Department of Neurology, University of Cincinnati Medical Center, UNITED STATES
| | | | - Yasmin Ninette Aziz
- Neurology and Rehabilitation Medicine, University of Cincinnati, UNITED STATES
| | | | | | - Marc Rodrigo-Gisbert
- Hospital Universitari Vall d'Hebron. Departament de Medicina, Universitat Autònoma de Barcelona. Barcelona. Spain
| | - Manuel Requena
- Neurology. Universitat Autònoma de Barcelona, Univ Hosp Vall d'Hebron, SPAIN
| | - Faddi Ghassan Saleh Velez
- Department of Neurology, Vascular Division, The University of Oklahoma Health Sciences Center, UNITED STATES
| | - Jorge G Ortiz Garcia
- Department of Neurology, Division of Critical Care Neurology, Division of Stroke and Cerebrovascular Disorders, The University of Oklahoma Health Sciences Center, UNITED STATES
| | | | - Adam de Havenon
- Department of Neurology, Yale University School of Medicine, UNITED STATES
| | | | | | | | | | | | - Randy Dunston
- Wake Forest University Baptist Medical Center, UNITED STATES
| | | | - Mary Penckofer
- Cooper Medical School of Rowan University, UNITED STATES
| | - James E Siegler
- Department of Neurology, University of Chicago, UNITED STATES
| | | | | | | | | | | | - João Pedro Marto
- Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, PORTUGAL
| | | | - Piers Klein
- Neurology, Boston University Chobanian & Avedisian School of Medicine, UNITED STATES
| | - Thanh N Nguyen
- Neurology, Radiology, Boston University Chobanian and Avedisian School of Medicine, UNITED STATES
| | | | | | - Anvesh Balabhadra
- Neurology, Hartford Hospital & University of Connecticut, UNITED STATES
| | - Shivam Patel
- Neurology, UConn School of Medicine, UNITED STATES
| | | | - Sheila Co Martins
- Stroke Unit, Neurology Service, Hospital de Clinicas de Porto Alegre, BRAZIL
| | | | - Young Dae Kim
- Department of Neurology, Yonsei University College of Medicine, KOREA, REPUBLIC OF
| | - Balaji Krishnaiah
- Neurology, University of Tennnessee Health Science Center, UNITED STATES
| | | | | | - Abid Y Qureshi
- Department of Neurology, University of Kansas Medical Center, UNITED STATES
| | - Sebastian Fridman
- Department of Clinical Neurological Sciences, University of Western Ontario - London Health Science Centre, CANADA
| | | | - Farid Khasiyev
- Neurology, Saint Louis University School of Medicine, UNITED STATES
| | - Guillermo Linares
- Souers Stroke Institute, Saint Louis University School of Medicine, UNITED STATES
| | | | | | - Sofia Vassilopoulou
- 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, GREECE
| | | | | | | | | | - Sleiman El Jamal
- Neurology, Rhode Island Hospital & Alpert Medical School of Brown University, UNITED STATES
| | - Shilin Liu
- University of Science and Technology, CHINA
| | | | | | | | - Rami Z Morsi
- Department of Neurology, University of Chicago, UNITED STATES
| | - Tareq Kass-Hout
- Department of Neurology, University of Chicago, UNITED STATES
| | - Feina Shi
- Department of Neurology, Sir Run Run Shaw Hospital of Zhejiang University, School of Medicine, CHINA
| | - Jinhua Zhang
- Department of Neurology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, CHINA
| | | | | | | | | | - Shayak Sen
- Cedars Sinai Medical Center, UNITED STATES
| | | | - Marwa Elnazeir
- Department of Neurology, University of Louisville, UNITED STATES
| | - Han Xiao
- Economics, University of California Santa Barbara, UNITED STATES
| | | | - Farhan Khan
- Neurology, Alpert Medical School, Brown University, UNITED STATES
| | - Christoph Stretz
- Neurology, Warren Alpert Medical School of Brown University, UNITED STATES
| | | | - Eric D Goldstein
- Neurology, Warren Alpert Medical School of Brown University, UNITED STATES
| | - Karen L Furie
- Department of Neurology, Rhode Island Hospital, UNITED STATES
| |
Collapse
|
8
|
Olindo S, Gaillard N, Chausson N, Turpinat C, Dargazanli C, Bourgeois-Beauvais Q, Signate A, Joux J, Mejdoubi M, Piotin M, Obadia M, Desilles JP, Delvoye F, Holay Q, Gory B, Richard S, Denier C, Robinet-Borgomano E, Carle X, Desal H, Guillon B, Viguier A, Lamy M, Pico F, Landais A, Boulanger M, Renou P, Gariel F, Jean P, Yann L, Papillon L, Marnat G, Smadja D. Clinical, imaging, and management features of symptomatic carotid web: Insight from CAROWEB registry. Int J Stroke 2024; 19:180-188. [PMID: 37724713 DOI: 10.1177/17474930231204343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
BACKGROUND Although carotid web (CaW) is increasingly diagnosed as a cause of cryptogenic stroke, data are still limited to monocentric small sample cohort. To broaden knowledge on symptomatic CaW, CAROWEB registry has been recently implemented. AIMS In a large cohort of symptomatic CaW patients, we described epidemiologic characteristics, admission clinical and imaging features, and the current management including the secondary preventive strategy choice made in comprehensive French Stroke Units. METHODS CAROWEB is an ongoing French observational multicenter registry enrolling consecutive CaW patients diagnosed after an ipsilateral ischemic stroke (IS) or transient ischemic attack (TIA). Submitted cases were validated by two experienced neurologist and neuroradiologist. Clinical, imaging, and management features were collected for this study. RESULTS Between June 2019 and December 2021, 244 cases were submitted by 14 centers, 42 rejected, and 202 included (IS, 91.6%; TIA, 7.9%; retinal infarction, 0.5%; mean age, 50.8 ± 12.2 years; female, 62.9%; Caucasian, 47.5%; Afro-Caribbean, 20.3%). IS patients showed median (interquartile range (IQR)) admission National Institutes of Health Stroke Scale (NIHSS) score, 8 (2-15); intracranial artery occlusion, 71.8%; ipsilateral chronic cerebral infarction (CCI), 16.3%; and reperfusion treatment, 57.3%. CaW was not identified during the mechanical thrombectomy procedure in 30 of 85 (35.3%) patients. Secondary prevention was invasive in 55.6% (stenting, n = 80; surgery, n = 30). In multivariable analysis, the invasive therapeutic option was associated with ipsilateral CCI (odds ratio (OR): 4.24 (1.27-14.2), p = 0.019) and inversely associated with risk factors (OR: 0.47 (0.24-0.91), p = 0.025) and admission NIHSS score (OR: 0.93 (0.89-0.97), p = 0.001). CONCLUSION CaW must be considered in all ethnic groups including Caucasians. Secondary prevention is heterogeneous in large French Stroke Centers. The absence of risk factors, milder severity strokes, and ipsilateral CCI were predictive variables of secondary invasive treatment. The high rate of invasive treatment suggests that medical treatment alone is deemed ineffective to avoid recurrence and emphasize the need of randomized trials.
Collapse
Affiliation(s)
- Stephane Olindo
- Service de Neurovasculaire, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Nicolas Gaillard
- Department of Neurology, Montpellier University Hospital, Montpellier, France
| | - Nicolas Chausson
- Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Cedric Turpinat
- Department of Neurology, Montpellier University Hospital, Montpellier, France
| | - Cyril Dargazanli
- Department of Neuroradiology, Montpellier University Hospital, Montpellier, France
| | | | - Aissatou Signate
- Department of Neurology, University Hospital of Martinique, Fort-de-France, France
| | - Julien Joux
- Department of Neurology, University Hospital of Martinique, Fort-de-France, France
| | - Mehdi Mejdoubi
- Department of Neuroradiology, University Hospital of Martinique, Fort-de-France, France
| | - Michel Piotin
- Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
| | - Mickael Obadia
- Department of Neurology, Rothschild Foundation Hospital, Paris, France
| | - Jean-Philippe Desilles
- Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
| | - François Delvoye
- Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
| | - Quentin Holay
- Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
| | - Benjamin Gory
- Department of Interventional and Diagnostic Neuroradiology, University Hospital of Nancy, Nancy, France
| | - Sébastien Richard
- Department of Neurology, University Hospital of Nancy, Nancy, France
| | | | | | - Xavier Carle
- Department of Neurology, Hôpital de La Timone, Marseille University Hospital, Marseille, France
| | - Hubert Desal
- Department of Neuroradiology, Nantes University Hospital, Nantes, France
| | - Benoit Guillon
- Department of Neurology, Nantes University Hospital, Nantes, France
| | - Alain Viguier
- Department of Neurology, Toulouse University Hospital, Toulouse, France
| | - Matthias Lamy
- Department of Neurology, Poitiers University Hospital, Poitiers, France
| | - Fernando Pico
- Department of Neurology, Versailles Hospital, Versailles, France
| | - Anne Landais
- Department of Neurology, University Hospital of Guadeloupe, Pointe-à-Pitre, France
| | | | - Pauline Renou
- Stroke Unit, University Hospital of Bordeaux, Bordeaux, France
| | - Florent Gariel
- Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France
| | - Papaxanthos Jean
- Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France
| | - Lhermitte Yann
- Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Lisa Papillon
- Stroke Unit, University Hospital of Bordeaux, Bordeaux, France
| | - Gaultier Marnat
- Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France
| | - Didier Smadja
- Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France
| |
Collapse
|
9
|
Fladt J, Kaesmacher J, Meinel TR, Bütikofer L, Strbian D, Eker OF, Albucher JF, Desal H, Marnat G, Papagiannaki C, Richard S, Requena M, Lapergue B, Pagano P, Ernst M, Wiesmann M, Boulanger M, Liebeskind DS, Gralla J, Fischer U. MRI vs CT for Baseline Imaging Evaluation in Acute Large Artery Ischemic Stroke: A Subanalysis of the SWIFT-DIRECT Trial. Neurology 2024; 102:e207922. [PMID: 38165324 DOI: 10.1212/wnl.0000000000207922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 09/18/2023] [Indexed: 01/03/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Whether MRI or CT is preferable for the evaluation of patients with suspected stroke remains a matter of debate, given that the imaging modality acquired at baseline may be a relevant determinant of workflow delays and outcomes with it, in patients with stroke undergoing acute reperfusion therapies. METHODS In this post hoc analysis of the SWIFT-DIRECT trial that investigated noninferiority of thrombectomy alone vs IV thrombolysis (IVT) + thrombectomy in patients with an acute ischemic anterior circulation large vessel occlusive stroke eligible to receive IVT within 4.5 hours after last seen well, we tested for a potential interaction between baseline imaging modality (MRI/MR-angiography [MRA] vs CT/CT-angiography [CTA]) and the effect of acute treatment (thrombectomy vs IVT + thrombectomy) on clinical and safety outcomes and procedural metrics (primary analysis). Moreover, we examined the association between baseline imaging modality and these outcomes using regression models adjusted for age, sex, baseline NIH Stroke Scale (NIHSS), occlusion location, and Alberta Stroke Program Early CT Score (ASPECTS) (secondary analysis). Endpoints included workflow times, the modified Rankin scale (mRS) score at 90 days, the rate of successful reperfusion, the odds for early neurologic deterioration within 24 hours, and the risk of symptomatic intracranial hemorrhage. The imaging modality acquired was chosen at the discretion of the treating physicians and commonly reflects center-specific standard procedures. RESULTS Four hundred five of 408 patients enrolled in the SWIFT-DIRECT trial were included in this substudy. Two hundred (49.4%) patients underwent MRI/MRA, and 205 (50.6%) underwent CT/CTA. Patients with MRI/MRA had lower NIHSS scores (16 [interquartile range (IQR) 12-20] vs 18 [IQR 14-20], p = 0.012) and lower ASPECTS (8 [IQR 6-9] vs 8 [IQR 7-9], p = 0.021) compared with those with CT/CTA. In terms of the primary analysis, we found no evidence for an interaction between baseline imaging modality and the effect of IVT + thrombectomy vs thrombectomy alone. Regarding the secondary analysis, MRI/MRA acquisition was associated with workflow delays of approximately 20 minutes, higher odds of functional independence at 90 days (adjusted odds ratio [aOR] 1.65, 95% CI 1.07-2.56), and similar mortality rates (aOR 0.73, 95% CI 0.36-1.47) compared with CT/CTA. DISCUSSION This post hoc analysis does not suggest treatment effect heterogeneity of IVT + thrombectomy vs thrombectomy alone in large artery stroke patients with different imaging modalities. There was no evidence that functional outcome at 90 days was less favorable following MRI/MRA at baseline compared with CT/CTA, despite significant workflow delays. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov Identifier: NCT03192332.
Collapse
Affiliation(s)
- Joachim Fladt
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Johannes Kaesmacher
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Thomas R Meinel
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Lukas Bütikofer
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Daniel Strbian
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Omer F Eker
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Jean-Francois Albucher
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Hubert Desal
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Gaultier Marnat
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Chrysanthi Papagiannaki
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Sebastien Richard
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Manuel Requena
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Bertrand Lapergue
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Paolo Pagano
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Marielle Ernst
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Martin Wiesmann
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Marion Boulanger
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - David S Liebeskind
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Jan Gralla
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| | - Urs Fischer
- From the Stroke Center and Department of Neurology (J.F., U.F.), University Hospital Basel and University of Basel; University Institute of Diagnostic and Interventional Neuroradiology (J.K., J.G.), and Department of Neurology (T.R.M., U.F.), Inselspital, Bern University Hospital and University of Bern; CTU Bern (L.B.), University of Bern, Switzerland; Department of Neurology (D.S.), Helsinki University Hospital, University of Helsinki, Finland; Department of Neuroradiology (O.F.E.), Hospices Civils de Lyon; Department of Diagnostic and Therapeutic Neuroradiology (J.-F.A.), Centre Hospitalier Universitaire de Toulouse; Department of Diagnostic and Interventional Neuroradiology (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes Université; Interventional and Diagnostic Neuroradiology (G.M.), CHU Bordeaux, University of Bordeaux; Department of Radiology (C.P.), CHU Rouen; Stroke Unit (S.R.), Department of Neurology, CHRU-Nancy, Université de Lorraine, France; Stroke Unit (M.R.), Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain; Department of Stroke and Diagnostic and Interventional Neuroradiology (B.L.), Foch Hospital, Suresnes, France; Department of Neuroradiology (P.P.), CHU Reims, France; Department of Neuroradiology (M.E.), University Medical Center Goettingen; Department of Neuroradiology (M.W.), University Hospital RWTH Aachen, Germany; Department of Neurology (M.B.), CHU Caen Normandie, University Caen Normandie, INSERM U1237, France; and Department of Neurology and Comprehensive Stroke Center (D.S.L.), David Geffen School of Medicine, University of California, Los Angeles
| |
Collapse
|
10
|
Anadani M, Finitsis S, Pop R, Darcourt J, Clarençon F, Richard S, de Havenon A, Liebeskind D, Marnat G, Bourcier R, Sibon I, Dargazanli C, Arquizan C, Blanc R, Lapergue B, Consoli A, Eugène F, Vannier S, Caroff J, Denier C, Boulanger M, Gauberti M, Saleme S, Macian F, Rosso C, Turc G, Ozkul-Wermester O, Papagiannaki C, Olivot JM, Le Bras A, Evain S, Wolff V, Timsit S, Gentric JC, Bourdain F, Veunac L, Maïer B, Ben Hassen W, Gory B. ASPECTS evolution after endovascular successful reperfusion in the early and extended time window. Interv Neuroradiol 2023:15910199231196953. [PMID: 37671452 DOI: 10.1177/15910199231196953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/07/2023] Open
Abstract
BACKGROUND The Alberta Stroke Program Early CT scan Score (ASPECTS) is a reliable imaging biomarker of infarct extent on admission but the value of 24-hour ASPECTS evolution in day-to-day practice is not well studied, especially after successful reperfusion. We aimed to assess the association between ASPECTS evolution after successful reperfusion with functional and safety outcomes, as well as to identify the predictors of ASPECTS evolution. METHODS We used data from an ongoing prospective multicenter registry. Stroke patients with anterior circulation large vessel occlusion treated with endovascular therapy (EVT) and achieved successful reperfusion (modified thrombolysis in cerebral ischemia (mTICI) 2b-3) were included. ASPECTS evolution was defined as one or more point decrease in ASPECTS at 24 hours. RESULTS A total of 2366 patients were enrolled. In a fully adjusted model, ASPECTS evolution was associated with lower odds of favorable outcome (modified Rankin Scale (mRS) score 0-2) at 90 days (adjusted odds ratio (aOR) = 0.46; 95% confidence interval (CI) = 0.37-0.57). In addition, ASPECTS evolution was a predictor of excellent outcome (90-day mRS 0-1) (aOR = 0.52; 95% CI = 0.49-0.57), early neurological improvement (aOR = 0.42; 95% CI = 0.35-0.51), and parenchymal hemorrhage (aOR = 2.64; 95% CI, 2.03-3.44). Stroke severity, admission ASPECTS, total number of passes, complete reperfusion (mTICI 3 vs. mTICI 2b-2c) and good collaterals emerged as predictors of ASPECTS evolution. CONCLUSION ASPECTS evolution is a strong predictor of functional and safety outcomes after successful endovascular therapy. Higher number of EVT attempts and incomplete reperfusion are associated with ASPECTS evolution at day 1.
Collapse
Affiliation(s)
- Mohammad Anadani
- Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA
| | - Stephanos Finitsis
- Aristotle University of Thessaloniki, Ahepa Hospital, Thessaoniki, Greece
| | - Raoul Pop
- Department of Neuroradiolology, CHU Strasbourg, France
| | - Jean Darcourt
- Department of Neuroradiolology, CHU Toulouse, France
| | | | - Sébastien Richard
- Department of Neurology, Université de Lorraine, CHRU-Nancy, Nancy, France
- CIC-P 1433, INSERM U1116, CHRU-Nancy, Nancy, France
| | - Adam de Havenon
- Department of Neurology, Yale School of Medicine, New Haven, CT, USA
| | - David Liebeskind
- Department of Neurology, Neurovascular Imaging Research Core & UCLA Stroke Center, University of California, Los Angeles, Los Angeles, CA, USA
| | - Gaultier Marnat
- Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France
| | - Romain Bourcier
- Department of Neuroradiology, University Hospital of Nantes, Nantes, France
| | - Igor Sibon
- Department of Neurology, Stroke Center, University Hospital of Bordeaux, France
| | - Cyril Dargazanli
- Department of Interventional Neuroradiology, CHRU Gui de Chauliac, Montpellier, France
| | | | - Raphaël Blanc
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Bertrand Lapergue
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Arturo Consoli
- Department of Diagnostic and Interventional Neuroradiology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - François Eugène
- Department of Neuroradiology, University Hospital of Rennes, France
| | | | - Jildaz Caroff
- Department of Neuroradiolology, CHU Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Christian Denier
- Department of Neurology, CHU Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | | | | | - Suzana Saleme
- Department of Neuroradiology, University Hospital of Limoges, Limoges, France
| | - Francisco Macian
- Department of Neurology, University Hospital of Limoges, Limoges, France
| | - Charlotte Rosso
- Department of Neurology, CHU Pitié-Salpêtrière, Paris, France
| | - Guillaume Turc
- Department of Neurology, Hôpital Saint-Anne, Paris, France
| | | | | | | | - Anthony Le Bras
- Department of Neurology, CH Bretagne Atlantique, Vannes, France
| | - Sarah Evain
- Department of Neuroradiolology, CH Bretagne Atlantique, Vannes, France
| | | | | | | | | | - Louis Veunac
- Department of Neuroradiolology, CH Côte Basque, Bayonne, France
| | - Benjamin Maïer
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Wagih Ben Hassen
- Department of Neuroradiolology, Hôpital Saint-Anne, Paris, France
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, CHRU-Nancy, Nancy, France
- Université de Lorraine, IADI, INSERM U1254, Nancy, France
| |
Collapse
|
11
|
Meinel TR, Kaesmacher J, Buetikofer L, Strbian D, Eker OF, Cognard C, Mordasini P, Deppeler S, Mendes Pereira V, Albucher JF, Darcourt J, Bourcier R, Guillon B, Papagiannaki C, Costentin G, Sibolt G, Räty S, Gory B, Richard S, Liman J, Ernst M, Boulanger M, Barbier C, Mechtouff L, Zhang L, Marnat G, Sibon I, Nikoubashman O, Reich A, Consoli A, Weisenburger D, Requena M, Garcia-Tornel A, Saleme S, Moulin S, Pagano P, Saliou G, Carrera E, Janot K, Boix M, Pop R, Della Schiava L, Luft A, Piotin M, Gentric JC, Pikula A, Pfeilschifter W, Arnold M, Siddiqui A, Froehler MT, Furlan AJ, Chapot R, Wiesmann M, Machi P, Diener HC, Kulcsar Z, Bonati L, Bassetti C, Escalard S, Liebeskind D, Saver JL, Fischer U, Gralla J. Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial. J Neurointerv Surg 2023; 15:e102-e110. [PMID: 35902234 DOI: 10.1136/jnis-2022-019207] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 07/13/2022] [Indexed: 11/04/2022]
Abstract
BACKGROUND We hypothesized that treatment delays might be an effect modifier regarding risks and benefits of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT). METHODS We used the dataset of the SWIFT-DIRECT trial, which randomized 408 patients to IVT+MT or MT alone. Potential interactions between assignment to IVT+MT and expected time from onset-to-needle (OTN) as well as expected time from door-to-needle (DTN) were included in regression models. The primary outcome was functional independence (modified Rankin Scale (mRS) 0-2) at 3 months. Secondary outcomes included mRS shift, mortality, recanalization rates, and (symptomatic) intracranial hemorrhage at 24 hours. RESULTS We included 408 patients (IVT+MT 207, MT 201, median age 72 years (IQR 64-81), 209 (51.2%) female). The expected median OTN and DTN were 142 min and 54 min in the IVT+MT group and 129 min and 51 min in the MT alone group. Overall, there was no significant interaction between OTN and bridging IVT assignment regarding either the functional (adjusted OR (aOR) 0.76, 95% CI 0.45 to 1.30) and safety outcomes or the recanalization rates. Analysis of in-hospital delays showed no significant interaction between DTN and bridging IVT assignment regarding the dichotomized functional outcome (aOR 0.48, 95% CI 0.14 to 1.62), but the shift and mortality analyses suggested a greater benefit of IVT when in-hospital delays were short. CONCLUSIONS We found no evidence that the effect of bridging IVT on functional independence is modified by overall or in-hospital treatment delays. Considering its low power, this subgroup analysis could have missed a clinically important effect, and exploratory analysis of secondary clinical outcomes indicated a potentially favorable effect of IVT with shorter in-hospital delays. Heterogeneity of the IVT effect size before MT should be further analyzed in individual patient meta-analysis of comparable trials. TRIAL REGISTRATION NUMBER URL: https://www. CLINICALTRIALS gov ; Unique identifier: NCT03192332.
Collapse
Affiliation(s)
- Thomas R Meinel
- Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Johannes Kaesmacher
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | | | - Daniel Strbian
- Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Omer Faruk Eker
- Department of Neuroradiology, Hospices Civils de Lyon, Lyon, France
| | - Christophe Cognard
- Department of Diagnostic and Therapeutic Neuroradiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Pasquale Mordasini
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Sandro Deppeler
- Neuro Clinical Trial Unit, Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Vitor Mendes Pereira
- Division of Neuroradiology and Division of Neurosurgery, Departments of Medical Imaging and Surgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | | | - Jean Darcourt
- Department of Neuroradiology, Hospices Civils de Lyon, Lyon, France
| | - Romain Bourcier
- Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | - Benoit Guillon
- Department of Neurology, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | | | | | - Gerli Sibolt
- Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Silja Räty
- Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy, Université de Lorraine, INSERM U1254, Nancy, France
| | - Sébastien Richard
- Department of Neurology, Stroke Unit, CHRU-Nancy, Université de Lorraine, INSERM U1116, Nancy, France
| | - Jan Liman
- Department of Neurology, Klinikum Nürnberg, Nürnberg, Germany
| | - Marielle Ernst
- Department of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen, Gottingen, Germany
| | - Marion Boulanger
- Deparment of Neurology, CHU Caen Normandie, University Caen Normandie, INSERM U1237, Caen, France
| | - Charlotte Barbier
- Department of Neuroradiology, CHU Caen Normandie, University Caen Normandie, INSERM U1237, Caen, France
| | - Laura Mechtouff
- Department of Vascular Neurology, Hospices Civils de Lyon, Lyon, France
| | - Liqun Zhang
- Department of Neurology, St George's University Hospital NHS Foundation Trust, London, UK
| | - Gaultier Marnat
- Department of Interventional and Diagnostic Neuroradiology, CHU Bordeaux, University of Bordeaux, Bordeaux, France
| | - Igor Sibon
- Stroke Unit, CHU Bordeaux, University of Bordeaux, Bordeaux, France
| | - Omid Nikoubashman
- Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Arno Reich
- Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany
| | - Arturo Consoli
- Department of Stroke and Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - David Weisenburger
- Department of Stroke and Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Manuel Requena
- Stroke Unit, Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain
- Interventional Neuroradiology, Department of Radiology, Hospital Vall d'Heborn, Barcelona, Spain
| | | | - Suzana Saleme
- Department of Neuroradiology, CHU Limoges, Limoges, France
| | | | - Paolo Pagano
- Department of Neuroradiology, CHU Reims, Reims, France
| | - Guillaume Saliou
- Service of Interventional and Diagnostic Radiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Emmanuel Carrera
- Department of Neurology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Kevin Janot
- Department of Diagnostic and Interventional Neuroradiology, Tours University Hospital, Tours, France
| | - Marti Boix
- Stroke Unit, Department of Neurosciences, University Hospital Germans Trias i Pujol, Barcelona, Spain
| | - Raoul Pop
- Department of Interventional Neuroradiology, Strasbourg University Hospitals, Strasbourg, France
| | | | - Andreas Luft
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- Department of Neurology, Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland
| | - Michel Piotin
- Department of interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France
| | | | - Aleksandra Pikula
- Department of Neurology, University Health Network - Toronto Western Hospital - University of Toronto, Toronto, Ontario, Canada
| | | | - Marcel Arnold
- Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Adnan Siddiqui
- Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA
| | - Michael T Froehler
- Vanderbilt Cerebrovascular Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Anthony J Furlan
- School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
| | - René Chapot
- Department of Intracranial Endovascular Therapy, Alfried-Krupp Krankenhaus, Essen, Germany
| | - Martin Wiesmann
- Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Paolo Machi
- Department of Neuroradiology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Hans-Christoph Diener
- Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Essen, Germany
| | - Zsolt Kulcsar
- Department of Neuroradiology, University Hospital of Zurich, Zurich, Switzerland
| | - Leo Bonati
- Department of Neurology, University Hospital Basel, Basel, Switzerland
| | - Claudio Bassetti
- Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| | - Simon Escalard
- Department of interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France
| | - David Liebeskind
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, UCLA, University of California, Los Angeles, California, USA
| | - Jeffrey L Saver
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, UCLA, University of California, Los Angeles, California, USA
| | - Urs Fischer
- Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
- Department of Neurology, University Hospital Basel, Basel, Switzerland
| | - Jan Gralla
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
| |
Collapse
|
12
|
Nehme A, Lanthier S, Boulanger M, Aouba A, Cacoub P, Jayne D, Makhzoum JP, Pagnoux C, Rhéaume M, Terrier B, Touzé E, de Boysson H. Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices. J Neurol 2023; 270:1989-1998. [PMID: 36538155 DOI: 10.1007/s00415-022-11528-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 12/09/2022] [Accepted: 12/10/2022] [Indexed: 12/25/2022]
Abstract
BACKGROUND Primary angiitis of the central nervous system (PACNS) is a rare disease, for which no validated guidelines exist. We report the findings of a survey on the clinical practice of physicians who manage adults with PACNS. METHODS An online survey was distributed through neurology, internal medicine, and rheumatology societies in Canada and Europe. Participants who were directly involved as treating physicians for at least two adult patients with PACNS were eligible for the survey. RESULTS Ninety-six physicians completed the survey. Most participants were neurologists (n = 38, 40%), internists (n = 34, 35%) or rheumatologists (n = 22, 23%). Participants obtained a CNS biopsy in a median of 25% (IQR: 5-50%) of suspected PACNS cases. When determining the degree to which eight scenarios justified a CNS biopsy, participants achieved fair inter-rater agreement (Gwet's AC2 0.30, 95% CI 0.23-0.41). For induction therapy, 81 (84%) participants reported using glucocorticoids and cyclophosphamide in > 50% of patients. After obtaining remission, 85 (89%) participants systematically introduced or maintained immunosuppressive therapy. Glucocorticoids were prescribed for a median of 12 months. Maintenance therapy with another immunosuppressant was continued for a median of 24 months. In patients who achieved remission, we explored how eight scenarios with different imaging and CSF results supported an increase in treatment. Inter-rater agreement was substantial if the patient was symptomatic (0.66, 95% CI 0.58-0.80) and moderate (0.50, 95% CI 0.45-0.60) if asymptomatic. CONCLUSION This survey illustrates current real-world management of PACNS and emphasizes several areas for which physicians still lack study-based evidence and/or clinical practice guidelines.
Collapse
Affiliation(s)
- Ahmad Nehme
- Caen Normandie University, Caen, France.
- Department of Neurology, Centre Hospitalier Universitaire de Caen-Normandie, Avenue de la Côte de Nacre, 14000, Caen, France.
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France.
| | - Sylvain Lanthier
- Department of Neurology, Hôpital du Sacré-cœur de Montréal, Université de Montréal, Montréal, Canada
| | - Marion Boulanger
- Caen Normandie University, Caen, France
- Department of Neurology, Centre Hospitalier Universitaire de Caen-Normandie, Avenue de la Côte de Nacre, 14000, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| | - Achille Aouba
- Caen Normandie University, Caen, France
- Department of Internal Medicine, Caen University Hospital, Caen, France
| | - Patrice Cacoub
- Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 75013, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, UMR 6211, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU i2B), 75005, Paris, France
| | - David Jayne
- Department of Medicine, University of Cambridge, Cambridge, UK
| | - Jean-Paul Makhzoum
- Department of Internal Medicine, Hôpital du Sacré-cœur de Montréal, Université de Montréal, Montréal, Canada
| | - Christian Pagnoux
- Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - Maxime Rhéaume
- Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France
| | - Benjamin Terrier
- Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris, Paris, France
| | - Emmanuel Touzé
- Caen Normandie University, Caen, France
- Department of Neurology, Centre Hospitalier Universitaire de Caen-Normandie, Avenue de la Côte de Nacre, 14000, Caen, France
- INSERM UMR-S U1237 PhIND/BB@C, Caen, France
| | - Hubert de Boysson
- Caen Normandie University, Caen, France
- Department of Internal Medicine, Caen University Hospital, Caen, France
| |
Collapse
|
13
|
Miller M, Boulanger M, Guo M, Turner M, Olson S, Eaton C, Hsu M, Feliciano J. PPD01.02 Identifying Physical, Social, Emotional, and Medical Needs of Lung Cancer Survivors with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
14
|
Anadani M, Januel AC, Finitsis S, Clarençon F, Richard S, Marnat G, Bourcier R, Sibon I, Dargazanli C, Arquizan C, Blanc R, Lapergue B, Consoli A, Eugene F, Vannier S, Caroff J, Denier C, Boulanger M, Gauberti M, Rouchaud A, Macian Montoro F, Rosso C, Ben Hassen W, Turc G, Ozkul-Wermester O, Papagiannaki C, Albucher JF, Le Bras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, de Havenon A, Liebeskind DS, Maier B, Gory B. Effect of intravenous thrombolysis before endovascular therapy on outcome according to collateral status: insight from the ETIS Registry. J Neurointerv Surg 2023; 15:14-19. [PMID: 35115393 DOI: 10.1136/neurintsurg-2021-018170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2021] [Accepted: 12/23/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND It is unknown whether collateral status modifies the effect of pretreatment intravenous thrombolysis (IVT) on the outcomes of patients with large vessel occlusions treated with endovascular therapy (EVT). We aimed to assess whether collateral status modifies the effect of IVT on the outcomes of EVT in clinical practice. METHODS We used data from the ongoing prospective multicentric Endovascular Treatment in Ischemic Stroke (ETIS) Registry in France. Patients with anterior circulation proximal large vessel occlusions treated with EVT within 6 hours of symptom onset were enrolled. Patients were divided into two groups based on pretreatment with IVT. The two groups were matched based on baseline characteristics. We tested the interaction between collateral status and IVT in unadjusted and adjusted models. RESULTS A total of 1589 patients were enrolled in the study, of whom 55% received IVT. Using a propensity score matching method, 724 no IVT patients were matched to 549 IVT patients. In propensity score weighted analysis, IVT was associated with higher odds of early neurological improvement (OR 1.74; 95% CI 1.33 to 2.26), favorable functional outcome (OR 1.66; 95% CI 1.23 to 2.24), excellent functional outcome (OR 2.04; 95% CI 1.47 to 2.83), and successful reperfusion (OR 2.18; 95% CI 1.51 to 3.16). IVT was not associated with mortality or hemorrhagic complications. There was no interaction between collateral status and IVT association with any of the outcomes. CONCLUSIONS Collateral status does not modify the effect of pretreatment IVT on the efficacy and safety outcomes of EVT.
Collapse
Affiliation(s)
- Mohammad Anadani
- Neurosurgery, Medical University of South Carolina - College of Medicine, Charleston, South Carolina, USA
| | | | - Stephanos Finitsis
- Neuroradiolology, University General Hospital of Thessaloniki AHEPA, Thessaoniki, Greece
| | - Frédéric Clarençon
- Interventional Neuroradiology, University Hospital Pitié Salpêtrière, Paris, France
| | - Sébastien Richard
- Neurology Stroke Unit, University Hospital Centre Nancy, Nancy, France
| | - Gaultier Marnat
- Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | | | | | - Cyril Dargazanli
- Department of Neuroradiology, University Hospital Centre Montpellier, Montpellier, France
| | | | - Raphael Blanc
- Interventional Neuroradiology, Fondation Rothschild, Paris, France
| | | | | | | | | | - Jildaz Caroff
- Department of Interventional Neuroradiology - NEURI Brain Vascular Center, Bicêtre Hospital, APHP, Le Kremlin Bicêtre, France
| | - Christian Denier
- Neurology, Hôpital Bicetre, Le Kremlin-Bicetre, Île-de-France, France
| | | | - Maxime Gauberti
- Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France
| | - Aymeric Rouchaud
- Interventional Neuroradiology, Centre Hospitalier Universitaire de Limoges, Limoges, France.,Department of Neurology, CHU Limoges, Limoges, France
| | | | - Charlotte Rosso
- Urgences Cérébro-Vasculaires, Pitié-Salpétrière Hospital, Paris, France
| | - Wagih Ben Hassen
- Interventional Neuroradiology, Saint Anne Hospital Centre, Paris, France.,INSERM U1166, Paris, France
| | - Guillaume Turc
- Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France
| | | | | | | | - Anthony Le Bras
- Department of Radiology, CH Bretagne Atlantique, Vannes, France.,CHU Rennes Service de Radiologie et d'Imagerie Médicale, Rennes, France
| | - Sarah Evain
- Department of Neurology, Centre Hospitalier Bretagne Atlantique, Vannes, France
| | - Valerie Wolff
- Stroke Unit, Strasbourg University Hospitals, Strasbourg, France
| | - Raoul Pop
- Interventional Neuroradiology, University Hospitals Strasbourg, Strasbourg, France.,Interventional Radiology, Institut de Chirurgie Guidée par l'Image, Strasbourg, France
| | - Serge Timsit
- Department of Neurology, CHU Brest, Brest, France
| | | | - Frederic Bourdain
- Neurology, Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France
| | - Louis Veunac
- Department of Radiology and Interventional Neuroradiology, CHU de Bordeaux, Bordeaux, France
| | - Adam de Havenon
- Department of Neurology, University of Utah, Salt Lake City, Utah, USA
| | | | - Benjamin Maier
- Interventional Neuroradiology, Adolphe de Rothschild Ophthalmological Foundation, Paris, France
| | - Benjamin Gory
- Department of Diagnostic and Interventional Neuroradiology, CHRU Nancy, Nancy, France
| | | |
Collapse
|
15
|
Marnat G, Holay Q, Darcourt J, Desilles JP, Obadia M, Viguier A, Caroff J, Denier C, Papillon L, Barreau X, Cognard C, Berge J, Bourgeois-Beauvais Q, Landais A, Boulanger M, Macian F, Guillon B, Pico F, Lamy M, Robinet-Borgomano E, Richard S, Gory B, Sibon I, Gaillard N, Chausson N, Olindo S. Dual-layer carotid stenting for symptomatic carotid web: Results from the Caroweb study. J Neuroradiol 2022; 50:444-448. [PMID: 36563743 DOI: 10.1016/j.neurad.2022.12.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 12/16/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND & PURPOSE Carotid Web (CaW) is a growingly recognized cause of ischemic stroke, associated with a high recurrence risk. Several therapeutic strategies have been proposed as a tertiary prevention including carotid stenting, endarterectomy and antithrombotic medications. Among these, carotid stenting with dual-layer stent may be promising to adequately cover the focal arterial dysplasia. Our aim was to investigate the safety and efficacy of the Casper stent in the treatment of symptomatic CaW. METHODS We conducted a retrospective analysis of consecutive patients presenting with a symptomatic CaW and included in the ongoing prospective observational multicenter CAROWEB registry. The study period was January 2015 to December 2021. Inclusion criteria were CaW treated with dual-layer Casper stent. Patients treated with other types of carotid stent, endarterectomy or antithrombotic medication were excluded. Clinical and radiological initial data and outcomes were recorded. RESULTS twenty-seven patients (with 28 caw) were included. median age was 52 (iqr: 46-68). median delay between index cerebrovascular event and cervical stenting was 9 days (IQR: 6-101). In all cases, the cervical carotid stenting was successfully performed. No major perioperative complication was recorded. No recurrent stroke or transient ischemic attack was observed during a median follow-up time of 272 days (IQR: 114-635). Long-term imaging follow-up was available in 25/28 (89.3%) stented CaW with a median imaging follow-up of 183 days (IQR: 107-676; range: 90-1542). No in-stent occlusion or stenosis was detected. CONCLUSION In this study, carotid stenting with dual-layer Casper stent in the treatment of symptomatic CaW was effective regarding stroke recurrence prevention and safe, without procedural nor delayed detected adverse event. However, the optimal therapeutic approach of symptomatic CaW still needs to be explored through randomized trials.
Collapse
Affiliation(s)
- Gaultier Marnat
- Department of Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | - Quentin Holay
- Department of Interventional Neuroradiology, Rothschild foundation hospital, Paris, France
| | - Jean Darcourt
- Department of Interventional and Diagnostic Neuroradiology, Toulouse University Hospital, Toulouse, France
| | - Jean-Philippe Desilles
- Department of Interventional Neuroradiology, Rothschild foundation hospital, Paris, France
| | - Michael Obadia
- Department of Neurology, Rothschild foundation hospital Paris, France
| | - Alain Viguier
- Department of Neurology, Toulouse University Hospital, Toulouse, France
| | - Jildaz Caroff
- Department of Interventional Neuroradiology, CHU Bicêtre APHP, Kremlin Bicêtre, France
| | - Christian Denier
- Department of Neurology, CHU Kremlin Bicêtre, Kremlin Bicêtre, France
| | - Lisa Papillon
- Department of Neurology, Stroke Unit, Bordeaux University Hospital, Bordeaux, France
| | - Xavier Barreau
- Department of Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | - Christophe Cognard
- Department of Interventional and Diagnostic Neuroradiology, Toulouse University Hospital, Toulouse, France
| | - Jerome Berge
- Department of Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | | | - Anne Landais
- Department of Neurology, Point à Pitre Hospital, Pointe à Pitre, France
| | - Marion Boulanger
- Department of Neurology, Caen University Hospital, Caen, University Caen Normandy, France
| | - Francisco Macian
- Department of Neurology, Limoges University Hospital, Limoges, France
| | - Benoit Guillon
- Department of Neurology, Nantes University Hospital, Nantes, France
| | - Fernando Pico
- Department of Neurology, Versailles Hospital, Le Chesnay, France
| | - Mathias Lamy
- Department of Neurology, Poitiers University Hospital, Poitiers, France
| | | | - Sébastien Richard
- Neurology Department, Nancy University Hospital, Nancy, France - INSERM U1116, Nancy, France
| | - Benjamin Gory
- France Department of Interventional and Diagnostic Neuroradiology, Nancy University Hospital, Nancy, France
| | - Igor Sibon
- Department of Neurology, Martinique University Hospital, Fort-de-France, France
| | - Nicolas Gaillard
- Department of Neurology, Montpellier University Hospital, Montpellier, France
| | - Nicolas Chausson
- Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Stephane Olindo
- Department of Neurology, Martinique University Hospital, Fort-de-France, France
| | | |
Collapse
|
16
|
Panni P, Lapergue B, Maïer B, Finitsis S, Clarençon F, Richard S, Marnat G, Bourcier R, Sibon I, Dargazanli C, Blanc R, Consoli A, Eugène F, Vannier S, Spelle L, Denier C, Boulanger M, Gauberti M, Saleme S, Macian F, Rosso C, Naggara O, Turc G, Ozkul-Wermester O, Papagiannaki C, Albucher JF, Darcourt J, Le Bras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, Arquizan C, Gory B. Clinical Impact and Predictors of Diffusion Weighted Imaging (DWI) Reversal in Stroke Patients with Diffusion Weighted Imaging Alberta Stroke Program Early CT Score 0-5 Treated by Thrombectomy : Diffusion Weighted Imaging Reversal in Large Volume Stroke. Clin Neuroradiol 2022; 32:939-950. [PMID: 35412044 DOI: 10.1007/s00062-022-01156-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Accepted: 03/02/2022] [Indexed: 12/15/2022]
Abstract
PURPOSE To determine whether reversal of DWI lesions (DWIr) on the DWI-ASPECTS (diffusion weighted imaging Alberta Stroke Program CT Score) template should serve as a predictor of 90-day clinical outcome in acute ischemic stroke (AIS) patients with pretreatment diffusion-weighted imaging (DWI)-ASPECTS 0-5 treated with thrombectomy, and to determine its predictors in current practice. METHODS We analyzed data of all consecutive patients included in the prospective multicenter national Endovascular Treatment in Ischemic Stroke Registry between 1 January 2015 and 31 December 2020 with a premorbid mRS ≤ 2, who presented with a pretreatment DWI-ASPECTS 0-5 score, underwent thrombectomy and had an available 24 h post-interventional MRI follow-up. Multivariable analyses were performed to evaluate the clinical impact of DWIr on early neurological improvement (ENI), 3‑month modified Rankin scale (mRS) score distribution (shift analysis) and to define independent predictors of DWIr. RESULTS Early neurological improvement was detected in 82/211 (41.7%) of patients while 3‑month functional independence was achieved by 75 (35.5%) patients. The DWI reversal (39/211, 18.9%) resulted an independent predictor of both ENI (aOR 3.6, 95% CI 1.2-7.7; p 0.018) and 3‑month clinical outcome (aOR for mRS shift: 2.2, 95% CI 1-4.6; p 0.030). Only successful recanalization (mTICI 2c-3) independently predicted DWIr in the studied population (aOR 3.3, 95% CI 1.3-7.9; p 0.009). CONCLUSION The DWI reversal occurs in a non-negligible proportion of DWI-ASPECTS 0-5 patients subjected to thrombectomy and significantly influences clinical outcome. The mTICI 2c-3 recanalization emerged as an independent DWIr predictor.
Collapse
Affiliation(s)
- Pietro Panni
- Department of Neuroradiology, Division of Interventional Neuroradiology, Department of Neurosurgery, San Raffaele University Hospital, Milan, Italy.
| | - Bertrand Lapergue
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Benjamin Maïer
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Stephanos Finitsis
- AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Sébastien Richard
- CHRU-Nancy, Department of Neurology, Stroke Unit, Université de Lorraine, 54000, Nancy, France.,CIC-P 1433, INSERM U1116, CHRU-Nancy, 54000, Nancy, France
| | - Gaultier Marnat
- Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, Bordeaux, France
| | - Romain Bourcier
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Igor Sibon
- Neurology, University Hospital of Bordeaux, Bordeaux, France
| | - Cyril Dargazanli
- Department of Interventional Neuroradiology, CHRU Gui de Chauliac, Montpellier, France
| | - Raphaël Blanc
- Department of Neuroradiology, University Hospital of Nantes, Nantes, France
| | - Arturo Consoli
- Diagnostic and Interventional Neuroradiology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - François Eugène
- Department of Neuroradiology, University Hospital of Rennes, Rennes, France
| | | | | | | | | | | | | | | | - Charlotte Rosso
- Department of Neurology, CHU Pitié-Salpétrière, Paris, France
| | | | - Guillaume Turc
- Department of Neurology, Hôpital Saint-Anne, Paris, France
| | | | | | | | | | - Anthony Le Bras
- Department of Neuroradiology, CHBA Bretagne Atlantique, Vannes, France
| | - Sarah Evain
- Neurology, CHBA Bretagne Atlantique, Vannes, France
| | - Valérie Wolff
- Department of Neurology, CHU Strasbourg, Strasbourg, France
| | - Raoul Pop
- Neuroradiology, CHU Strasbourg, Strasbourg, France
| | - Serge Timsit
- Department of Neurology, CHU Brest, Brest, France
| | | | | | | | | | - Benjamin Gory
- CHRU-Nancy, Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, 54000, Nancy, France.,IADI, INSERM U1254, Université de Lorraine, 54000, Nancy, France
| | | |
Collapse
|
17
|
Nehme A, Boulanger M, Aouba A, Pagnoux C, Zuber M, Touzé E, de Boysson H. Diagnostic and therapeutic approach to adult central nervous system vasculitis. Rev Neurol (Paris) 2022; 178:1041-1054. [PMID: 36156251 DOI: 10.1016/j.neurol.2022.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 05/16/2022] [Indexed: 12/14/2022]
Abstract
The clinical manifestations of central nervous system (CNS) vasculitis are highly variable. In the absence of a positive CNS biopsy, CNS vasculitis is particularly suspected when markers of both vascular disease and inflammation are present. To facilitate the clinical and therapeutic approach to this rare condition, CNS vasculitis can be classified according to the size of the involved vessels. Vascular imaging is used to identify medium vessel disease. Small vessel disease can only be diagnosed with a CNS biopsy. Medium vessel vasculitis usually presents with focal neurological signs, while small vessel vasculitis more often leads to cognitive deficits, altered level of consciousness and seizures. Markers of CNS inflammation include cerebrospinal fluid pleocytosis or elevated protein levels, and vessel wall, parenchymal or leptomeningeal enhancement. The broad range of differential diagnoses of CNS vasculitis can be narrowed based on the disease subtype. Common mimickers of medium vessel vasculitis include intracranial atherosclerosis and reversible cerebral vasoconstriction syndrome. The diagnostic workup aims to answer two questions: is the neurological presentation secondary to a vasculitic process, and if so, is the vasculitis primary (i.e., primary angiitis of the CNS) or secondary (e.g., to a systemic vasculitis, connective tissue disorder, infection, malignancy or drug use)? In primary angiitis of the CNS, glucocorticoids and cyclophosphamide are most often used for induction therapy, but rituximab may be an alternative. Based on the available evidence, all patients should receive maintenance immunosuppression. A multidisciplinary approach is necessary to ensure an accurate and timely diagnosis and to improve outcomes for patients with this potentially devastating condition.
Collapse
Affiliation(s)
- A Nehme
- Normandie University, Caen, France; Department of Neurology, Caen University Hospital, Caen, France; Inserm UMR-S U1237 PhIND/BB@C, Caen, France.
| | - M Boulanger
- Normandie University, Caen, France; Department of Neurology, Caen University Hospital, Caen, France; Inserm UMR-S U1237 PhIND/BB@C, Caen, France
| | - A Aouba
- Normandie University, Caen, France; Department of Internal Medicine, Caen University Hospital, Caen, France
| | - C Pagnoux
- Vasculitis clinic, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - M Zuber
- Department of Neurology, Saint-Joseph Hospital, Paris, France; Université Paris Cité, Paris, France
| | - E Touzé
- Normandie University, Caen, France; Department of Neurology, Caen University Hospital, Caen, France; Inserm UMR-S U1237 PhIND/BB@C, Caen, France
| | - H de Boysson
- Normandie University, Caen, France; Department of Internal Medicine, Caen University Hospital, Caen, France
| |
Collapse
|
18
|
Nehme A, Lanthier S, Boulanger M, Aouba A, Cacoub P, Jayne D, Makhzoum J, Pagnoux C, Rhéaume M, Samson M, Terrier B, Touzé E, De Boysson H. Diagnostic et prise en charge des vascularites primitives du système nerveux central : évaluation des pratiques par un sondage international. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
19
|
de Graaf L, Talibov M, Boulanger M, Bureau M, Robelot E, Lebailly P, Baldi I. Health of greenspace workers: Morbidity and mortality data from the AGRICAN cohort. Environ Res 2022; 212:113375. [PMID: 35533714 DOI: 10.1016/j.envres.2022.113375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 04/13/2022] [Accepted: 04/25/2022] [Indexed: 06/14/2023]
Abstract
INTRODUCTION Knowledge on the health of greenspace workers is scarce, even though they are exposed to many occupational hazards. The aim of this study was to analyze mortality by cause, prevalence of some non-cancer diseases, and incidence of the main cancers among greenspace workers. METHODS A sub-cohort of greenspace workers was formed within the AGRICAN cohort. Demographic information, health characteristics and self-reported diseases at enrollment were described separately in terms of frequencies (%), median and Interquartile Range (IQR) for greenspace workers, farmers, and other non-agricultural workers. Causes of death and cancer incidence were identified through linkage with cancer registries from enrollment (2005-2007) to 2015. Hazard ratio (HR) and 95% Confidence Intervals [95% CI] were estimated using Cox proportional hazard regression with age as the underlying timescale. RESULTS The sub-cohort included 6247 greenspace workers who were higher proportion men, younger and more frequently smokers than farmers and non-agricultural workers. Male and female greenspace workers reported more history of allergic diseases; and males, more history of depression. Compared to other workers male greenspace workers showed a non-significant higher mortality from ischemic cardiological diseases (HR = 1.14 [0.81-1.60]). Incidence was higher in male greenspace workers than farmers for overall cancer (HR = 1.15 [1.04-1.27]), cancer of the prostate (HR = 1.21 [1.02-1.44]), thyroid (HR = 2.84 [1.26-6.41]), testis (HR = 3.98 [1.50-10.58]) and skin melanoma (HR = 2.15 [1.33-3.47]). Non-significant increased risks were also found for sarcomas, larynx and breast. In women, risk of breast cancer was higher in greenspace workers than in farmers (HR = 1.71 [1.17-2.50]). CONCLUSIONS Whereas greenspace workers have often been included with other pesticide applicators in epidemiological studies, our analyses highlighted the differences between these two populations. They demonstrate the need to study them separately and to investigate more thoroughly the role of specific occupational exposures such as pesticides as well as the effect on women.
Collapse
Affiliation(s)
- L de Graaf
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France.
| | - M Talibov
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - M Boulanger
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - M Bureau
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - E Robelot
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - P Lebailly
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - I Baldi
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France; Service Santé Travail Environnement - CHU de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France
| |
Collapse
|
20
|
Olivot J, Finitsis S, Lapergue B, Marnat G, Sibon I, Richard S, Viguier A, Cognard C, Mazighi M, Gory B, Piotin M, Blanc R, Redjem H, Escalard S, Desilles J, Delvoye F, Smajda S, Maïer B, Hebert S, Mazighi M, Obadia M, Sabben C, Seners P, Raynouard I, Corabianu O, de Broucker T, Manchon E, Taylor G, Maacha MB, Thion L, Lecler A, Savatovsjy J, Wang A, Evrard S, Tchikviladze M, Ajili N, Lapergue B, Weisenburger‐Lile D, Gorza L, Buard G, Coskun O, Consoli A, Di Maria F, Rodesh G, Zimatore S, Leguen M, Gratieux J, Pico F, Rakotoharinandrasana H, Tassan P, Poll R, Marinier S, Nighoghossian N, Riva R, Eker O, Turjman F, Derex L, Cho T, Mechtouff L, Lukaszewicz A, Philippeau F, Cakmak S, Blanc‐Lasserre K, Vallet A, Marnat G, Gariel F, Barreau X, Berge J, Menegon P, Sibon I, Lucas L, Olindo S, Renou P, Sagnier S, Poli M, Debruxelles S, Rouanet F, Tourdias T, Liegey J, Briau P, Pangon N, Bourcier R, Detraz L, Daumas‐Duport B, Alexandre P, Roy M, Lenoble C, Desal H, Guillon B, de Gaalon S, Preterre C, Gory B, Bracard S, Anxionnat R, Braun M, Derelle A, Liao L, Zhu F, Schmitt E, Planel S, Richard S, Humbertjean L, Mione G, Lacour J, Douarinou M, Audibert G, Voicu M, Alb I, Reitter M, Brezeanu M, Masson A, Tabarna A, Podar I, Bourst P, Beaumont M, Chen (Mitchelle) B, Guy S, Georges V, Bechiri F, Macian‐Montoro F, Saleme S, Mounayer C, Rouchaud A, Gimenez L, Cosnard A, Costalat V, Arquizan C, Dargazanli C, Gascou G, Lefèvre P, Derraz I, Riquelme C, Gaillard N, Mourand I, Corti L, Cagnazzo F, ter Schiphorst A, Alias Q, Boustia F, Ferre J, Raoult H, Gauvrit J, Vannier S, Guillen M, Ronziere T, Lassalle V, Tracol C, Malrain C, Boinet S, Clarençon F, Shotar E, Sourour N, Lenck S, Premat K, Samson Y, Léger A, Crozier S, Baronnet F, Alamowitch S, Bottin L, Yger M, Degos V, Spelle L, Denier C, Chassin O, Chalumeau V, Caroff J, Chassin O, Venditti L, Sarov M, Legris N, Naggara O, Hassen WB, Boulouis G, Rodriguez‐Régent C, Trystram D, Kerleroux B, Turc G, Domigo V, Lamy C, Birchenall J, Isabel C, Lun F, Viguier A, Cognard C, Januel A, Olivot J, Raposo N, Bonneville F, Albucher J, Calviere L, Darcourt J, Bellanger G, Tall P, Touze E, Barbier C, Schneckenburger R, Boulanger M, Cogez J, Guettier S, Gauberti M, Timsit S, Gentric J, Ognard J, Merrien FM, Wermester OO, Massardier E, Papagiannaki C, Triquenot A, Lefebvre M, Bourdain F, Bernady P, Lagoarde‐Segot L, Cailliez H, Veunac L, Higue D, Wolff V, Quenardelle V, Lauer V, Gheoca R, Pierre‐Paul I, Pop R, Beaujeux R, Mihoc D, Manisor M, Pottecher J, Meyer A, Chamaraux‐Tran T, Le Bras A, Evain S, Le Guen A, Richter S, Hubrecht R, Demasles S, Barroso B, Sablot D, Farouil G, Tardieu M, Smadja P, Aptel S, Seiler I. Parenchymal hemorrhage rate is associated with time to reperfusion and outcome. Ann Neurol 2022; 92:882-887. [DOI: 10.1002/ana.26478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 08/08/2022] [Accepted: 08/11/2022] [Indexed: 11/08/2022]
Affiliation(s)
| | | | - Bertrand Lapergue
- Department of Neurology Foch Hospital Versailles Saint‐Quentin en Yvelines University Suresnes France
| | - Gaultier Marnat
- Department of Diagnostic and Interventional Neuroradiology University Hospital of Bordeaux France
| | - Igor Sibon
- Department of Neurology, Stroke Center University Hospital of Bordeaux France
| | - Sebastien Richard
- Université de Lorraine, CHRU‐Nancy, Department of Neurology, Stroke Unit F‐54000 Nancy France
- CIC‐P 1433 , INSERM U1116, CHRU‐Nancy, F‐54000 Nancy France
| | - Alain Viguier
- Acute Stroke Unit‐ CIC 1436‐UMR 1214, CHU Toulouse France
| | - Christophe Cognard
- Department of Interventional and Diagnostic Neuroradiolology CHU Toulouse France
| | - Mikael Mazighi
- Department of Interventional Neuroradiology FHU Neurovasc, INSERM 1148, Université de Paris Cité Rothschild Foundation, Paris France
- Diagnostic and Therapeutic Neuroradiology, F‐54000 Nancy France
| | - Benjamin Gory
- Université de Lorraine, IADI, INSERM U1254 F‐54000 Nancy France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Schneckenburger R, Boulanger M, Watrin M, Le Du G, Morello R, Touzé E. Incidence and outcomes of acute cerebrovascular events: methodology of the population-based Normandy Stroke Study. Neuroepidemiology 2022; 57:112-120. [PMID: 35820376 DOI: 10.1159/000525408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 05/30/2022] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The number of strokes has been steadily increasing due to the ageing of the population and its management has changed dramatically in recent years. Nevertheless, there are few unbiased epidemiological studies to investigate the incidence of strokes and their long-term prognosis. METHODS The Normandy Stroke Study (NSS) is a prospective population-based study of all strokes and transient ischemic attacks in a large urban, suburban, and rural area in the Northwest of France. It is designed to meet the current gold standard in stroke epidemiological study by using multiple overlapping sources for case identification. It also aims to assess the impact of socio-economic disparities and long-term prognosis of stroke through an additional follow-up up to three years after the event to better understand the functional and cognitive prognostic of stroke as well as the quality of life in patients after stroke. CONCLUSION NSS will provide important data on epidemiology and long-term consequences of stroke at the population level and will help care providers to adapt resource allocation.
Collapse
|
22
|
Fischer U, Kaesmacher J, Strbian D, Eker O, Cognard C, Plattner PS, Bütikofer L, Mordasini P, Deppeler S, Pereira VM, Albucher JF, Darcourt J, Bourcier R, Benoit G, Papagiannaki C, Ozkul-Wermester O, Sibolt G, Tiainen M, Gory B, Richard S, Liman J, Ernst MS, Boulanger M, Barbier C, Mechtouff L, Zhang L, Marnat G, Sibon I, Nikoubashman O, Reich A, Consoli A, Lapergue B, Ribo M, Tomasello A, Saleme S, Macian F, Moulin S, Pagano P, Saliou G, Carrera E, Janot K, Hernández-Pérez M, Pop R, Schiava LD, Luft AR, Piotin M, Gentric JC, Pikula A, Pfeilschifter W, Arnold M, Siddiqui AH, Froehler MT, Furlan AJ, Chapot R, Wiesmann M, Machi P, Diener HC, Kulcsar Z, Bonati LH, Bassetti CL, Mazighi M, Liebeskind DS, Saver JL, Gralla J. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet 2022; 400:104-115. [PMID: 35810756 DOI: 10.1016/s0140-6736(22)00537-2] [Citation(s) in RCA: 121] [Impact Index Per Article: 60.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 03/02/2022] [Accepted: 03/15/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND Whether thrombectomy alone is equally as effective as intravenous alteplase plus thrombectomy remains controversial. We aimed to determine whether thrombectomy alone would be non-inferior to intravenous alteplase plus thrombectomy in patients presenting with acute ischaemic stroke. METHODS In this multicentre, randomised, open-label, blinded-outcome trial in Europe and Canada, we recruited patients with stroke due to large vessel occlusion confirmed with CT or magnetic resonance angiography admitted to endovascular centres. Patients were randomly assigned (1:1) via a centralised web server using a deterministic minimisation method to receive stent-retriever thrombectomy alone or intravenous alteplase plus stent-retriever thrombectomy. In both groups, thrombectomy was initiated as fast as possible with any commercially available Solitaire stent-retriever revascularisation device (Medtronic, Irvine, CA, USA). In the combined treatment group, intravenous alteplase (0·9 mg/kg bodyweight, maximum dose 90 mg per patient) was administered as early as possible after randomisation for 60 min with 10% of the calculated dose given as an initial bolus. Personnel assessing the primary outcome were masked to group allocation; patients and treating physicians were not. The primary binary outcome was a score of 2 or less on the modified Rankin scale at 90 days. We assessed the non-inferiority of thrombectomy alone versus intravenous alteplase plus thrombectomy in all randomly assigned and consenting patients using the one-sided lower 95% confidence limit of the Mantel-Haenszel risk difference, with a prespecified non-inferiority margin of 12%. The main safety endpoint was symptomatic intracranial haemorrhage assessed in all randomly assigned and consenting participants. This trial is registered with ClinicalTrials.gov, NCT03192332, and is closed to new participants. FINDINGS Between Nov 29, 2017, and May 7, 2021, 5215 patients were screened and 423 were randomly assigned, of whom 408 (201 thrombectomy alone, 207 intravenous alteplase plus thrombectomy) were included in the primary efficacy analysis. A modified Rankin scale score of 0-2 at 90 days was reached by 114 (57%) of 201 patients assigned to thrombectomy alone and 135 (65%) of 207 patients assigned to intravenous alteplase plus thrombectomy (adjusted risk difference -7·3%, 95% CI -16·6 to 2·1, lower limit of one-sided 95% CI -15·1%, crossing the non-inferiority margin of -12%). Symptomatic intracranial haemorrhage occurred in five (2%) of 201 patients undergoing thrombectomy alone and seven (3%) of 202 patients receiving intravenous alteplase plus thrombectomy (risk difference -1·0%, 95% CI -4·8 to 2·7). Successful reperfusion was less common in patients assigned to thrombectomy alone (182 [91%] of 201 vs 199 [96%] of 207, risk difference -5·1%, 95% CI -10·2 to 0·0, p=0·047). INTERPRETATION Thrombectomy alone was not shown to be non-inferior to intravenous alteplase plus thrombectomy and resulted in decreased reperfusion rates. These results do not support omitting intravenous alteplase before thrombectomy in eligible patients. FUNDING Medtronic and University Hospital Bern.
Collapse
Affiliation(s)
- Urs Fischer
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
| | - Johannes Kaesmacher
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Daniel Strbian
- Department of Neurology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Omer Eker
- Department of Neuroradiology, Hospices Civils de Lyon, Lyon, France
| | - Christoph Cognard
- Department of Diagnostic and Therapeutic Neuroradiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Patricia S Plattner
- Neuro Clinical Trial Unit, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | | | - Pasquale Mordasini
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Sandro Deppeler
- Neuro Clinical Trial Unit, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Vitor M Pereira
- Division of Neurosurgery, Department of Surgery and Medical Imaging, St Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | | | - Jean Darcourt
- Department of Diagnostic and Therapeutic Neuroradiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Romain Bourcier
- Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | - Guillon Benoit
- Department of Neurology, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | | | | | - Gerli Sibolt
- Department of Neurology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Marjaana Tiainen
- Department of Neurology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology, INSERM U1254, CHRU-Nancy, Université de Lorraine, Nancy, France
| | - Sébastien Richard
- Department of Neurology, Stroke Unit, INSERM U1116, CHRU-Nancy, Université de Lorraine, Nancy, France
| | - Jan Liman
- Department of Neurology, University Medical Center Goettingen, Goettingen, Germany
| | - Marielle Sophie Ernst
- Department of Neuroradiology, University Medical Center Goettingen, Goettingen, Germany
| | - Marion Boulanger
- Department of Neurology, CHU Caen Normandie, University Caen Normandie, INSERM U1237, Caen, France
| | - Charlotte Barbier
- Department of Neuroradiology, CHU Caen Normandie, University Caen Normandie, INSERM U1237, Caen, France
| | - Laura Mechtouff
- Department of Vascular Neurology, Hospices Civils de Lyon, Lyon, France
| | - Liqun Zhang
- Department of Neurology, St George's University Hospital NHS Foundation Trust, London, UK
| | - Gaultier Marnat
- Department of Interventional and Diagnostic Neuroradiology, CHU Bordeaux, University of Bordeaux, Bordeaux, France
| | - Igor Sibon
- Stroke Unit, CHU Bordeaux, University of Bordeaux, Bordeaux, France
| | - Omid Nikoubashman
- Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Arno Reich
- Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany
| | - Arturo Consoli
- Department of Stroke and Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Bertrand Lapergue
- Department of Stroke and Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France
| | - Marc Ribo
- Stroke Unit, Department of Neurology, Hospital Vall d'Heborn, Barcelona, Spain
| | - Alejandro Tomasello
- Interventional Neuroradiology, Department of Radiology, Hospital Vall d'Heborn, Barcelona, Spain
| | - Suzana Saleme
- Department of Neuroradiology, University Hospital of Limoges, Limoges, France
| | - Francisco Macian
- Department of Neurology, University Hospital of Limoges, Limoges, France
| | | | - Paolo Pagano
- Department of Neuroradiology, CHU Reims, Reims, France
| | - Guillaume Saliou
- Service of Interventional and Diagnostic Radiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Emmanuel Carrera
- Department of Neurology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Kevin Janot
- Department of Diagnostic and Interventional Neuroradiology, Tours University Hospital, Tours, France
| | - María Hernández-Pérez
- Stroke Unit, Department of Neurosciences, University Hospital Germans Trias i Pujol, Barcelona, Spain
| | - Raoul Pop
- Department of Interventional Neuroradiology, Strasbourg University Hospitals, Strasbourg, France
| | | | - Andreas R Luft
- Department of Neurology, University Hospital of Zurich, Zurich, Switzerland; Cereneo, Center for Neurology and Rehabilitation, Vitznau, Switzerland
| | - Michel Piotin
- Department of Interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France
| | - Jean Christophe Gentric
- Department of Neuroradiology, Brest University Hospital, Brest, France; GETBO, INSERM Unit UMR 1034, Brest, France
| | - Aleksandra Pikula
- Division of Neurology, Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
| | | | - Marcel Arnold
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Adnan H Siddiqui
- Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, NY, USA
| | - Michael T Froehler
- Vanderbilt Cerebrovascular Program, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Anthony J Furlan
- School of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - René Chapot
- Department of Intracranial Endovascular Therapy, Alfried Krupp Krankenhaus Essen, Essen, Germany
| | - Martin Wiesmann
- Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany
| | - Paolo Machi
- Department of Neuroradiology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Hans-Christoph Diener
- Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology IMIBE), Essen, Germany
| | - Zsolt Kulcsar
- Department of Neuroradiology, University Hospital of Zurich, Zurich, Switzerland
| | - Leo H Bonati
- Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Claudio L Bassetti
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Mikael Mazighi
- Department of Neurology, Lariboisière Hospital, University of Paris, FHU NeuroVasc, INSERM 1148, Paris, France; Department of Interventional Neuroradiology, Adolphe de Rothschild Hospital Foundation, University of Paris, FHU NeuroVasc, INSERM 1148, Paris, France
| | - David S Liebeskind
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Jeffrey L Saver
- Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Jan Gralla
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| |
Collapse
|
23
|
de Havenon A, Elhorany M, Boulouis G, Naggara O, Darcourt J, Clarençon F, Richard S, Marnat G, Bourcier R, Sibon I, Arquizan C, Dargazanli C, Maïer B, Seners P, Lapergue B, Consoli A, Eugene F, Vannier S, Caroff J, Denier C, Boulanger M, Gauberti M, Rouchaud A, Macian F, Rosso C, Turc G, Ozkul-Wermester O, Papagiannaki C, Albucher JF, Le Bras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, Fahed R, Finitsis SN, Gory B. Thrombectomy in basilar artery occlusions: impact of number of passes and futile reperfusion. J Neurointerv Surg 2022; 15:422-427. [PMID: 35450929 DOI: 10.1136/neurintsurg-2022-018715] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 04/05/2022] [Indexed: 11/04/2022]
Abstract
BACKGROUND The number of mechanical thrombectomy (MT) passes is strongly associated with angiographic reperfusion as well as clinical outcomes in patients with anterior circulation ischemic stroke. However, these associations have not been analyzed in patients with basilar artery occlusion (BAO). We investigated the influence of the number of MT passes on the degree of reperfusion and clinical outcomes, and compared outcome after ≤3 passes versus >3 passes. METHODS We used data from the prospective multicentric Endovascular Treatment in Ischemic Stroke (ETIS) Registry at 18 sites in France. Patients with BAO treated with MT were included. The primary outcome was a favorable outcome, defined as a modified Rankin Scale score of 0-3 at 90 days. We fit mixed multiple regression models, with center as a random effect. RESULTS We included 275 patients. Successful recanalization (modified Thrombolysis In Cerebral Infarction (mTICI) 2b-3) was achieved in 88.4%, and 41.8% had a favorable outcome. The odds ratio for favorable outcome with each pass above 1 was 0.41 (95% CI 0.23 to 0.73) and for recanalization (mTICI 2b-3) it was 0.70 (95% CI 0.57 to 0.87). In patients with ≤3 passes, the rate of favorable outcome in recanalized versus non-recanalized patients was 50.5% versus 10.0% (p=0.001), while in those with >3 passes it was 16.7% versus 15.2% (p=0.901). CONCLUSIONS We found that BAO patients had a significant relationship between the number of MT passes and both recanalization and favorable functional outcome. We further found that the benefit of recanalization in BAO patients was significant only when recanalization was achieved within three passes, encouraging at least three passes before stopping the procedure.
Collapse
Affiliation(s)
- Adam de Havenon
- Department of Neurology, Yale University, New Haven, Connecticut, USA
| | - Mahmoud Elhorany
- Interventional Neuroradiology, Hopital Universitaire Pitie Salpetriere, Paris, France
| | | | | | | | - Frédéric Clarençon
- Sorbonne Université, Paris, France.,Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Sébastien Richard
- Neurology Stroke Unit, University Hospital Centre Nancy, Nancy, France
| | - Gaultier Marnat
- Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | | | | | | | - Cyril Dargazanli
- Neuroradiology, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France
| | - Benjamin Maïer
- Neuroradiology, Adolphe de Rothschild Ophthalmological Foundation Department of Interventional Neuroradiology, Paris, Île-de-France, France
| | - Pierre Seners
- Adolphe de Rothschild Ophthalmological Foundation Department of Interventional Neuroradiology, Paris, Île-de-France, France
| | - Bertrand Lapergue
- Versailles Saint-Quentin-en-Yvelines University, Versailles, Île-de-France, France
| | - Arturo Consoli
- Diagnostic and Interventional Neuroradiology, Hospital Foch, Suresnes, France.,Interventional Neurovascular Unit, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
| | | | | | - Jildaz Caroff
- Department of Interventional Neuroradiology - NEURI Brain Vascular Center, Bicêtre Hospital, APHP, Le Kremlin Bicêtre, France
| | | | | | | | - Aymeric Rouchaud
- Interventional Neuroradiology, Centre Hospitalier Universitaire de Limoges, Limoges, France.,Univ. Limoges, CNRS, XLIM, UMR 7252, Limoges, France
| | | | - Charlotte Rosso
- Urgences Cérébro-Vasculaires, Pitié-Salpétrière Hospital, Paris, France
| | - Guillaume Turc
- Neurology, GHU Paris Psychiatrie et Neurosciences, Paris, France
| | | | | | | | - Anthony Le Bras
- Department of Radiology, CH Bretagne Atlantique, Vannes, France.,CHU Rennes Service de radiologie et d'imagerie médicale, Rennes, France
| | - Sarah Evain
- Department of Neurology, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France
| | - Valerie Wolff
- Stroke Unit, Strasbourg University Hospitals, Strasbourg, France
| | - Raoul Pop
- Interventional Neuroradiology, University Hospitals Strasbourg, Strasbourg, France.,Interventional Radiology, Institut de Chirurgie Guidée par l'Image, Strasbourg, France
| | - Serge Timsit
- Department of Neurology, CHU Brest, Brest, France
| | | | | | - Louis Veunac
- Department of Radiology, Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France
| | - Robert Fahed
- Medicine - Neurology, Ottawa Hospital, Ottawa, Ontario, Canada.,Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Stephanos Nikolaos Finitsis
- Radiology, Centre Hospitalier de L'Universite de Montreal, Montreal, Québec, Canada.,Radiology, Centre Hospitalier de L'Universite de Montreal, Montreal, Québec, Canada
| | - Benjamin Gory
- Department of Diagnostic and Interventional Neuroradiology, CHRU Nancy, Nancy, Lorraine, France
| | | |
Collapse
|
24
|
Pop R, Finitsis SN, Arquizan C, Elhorany M, Naggara O, Darcourt J, Clarençon F, Richard S, Marnat G, Bourcier R, Sibon I, Dargazanli C, Blanc R, Lapergue B, Consoli A, Eugene F, Vannier S, Caroff J, Denier C, Boulanger M, Gauberti M, Rouchaud A, Macian F, Rosso C, Turc G, Ozkul-Wermester O, Albucher JF, Le Bras A, Evain S, Wolff V, Timsit S, Gentric JC, Bourdain F, Veunac L, Papagiannaki C, Gory B. Poor clinical outcome despite successful basilar occlusion recanalization in the early time window: incidence and predictors. J Neurointerv Surg 2022; 15:415-421. [PMID: 35428738 DOI: 10.1136/neurintsurg-2022-018769] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 04/03/2022] [Indexed: 11/04/2022]
Abstract
BackgroundEndovascular treatment (EVT) for basilar artery occlusions (BAO) is associated with a higher rate of futile recanalization compared with anterior circulation procedures. We aimed to identify the incidence and predictors of poor clinical outcome despite successful reperfusion in current clinical practice.MethodsWe used data from the ETIS (Endovascular Treatment in Ischemic Stroke) registry, a prospective multicenter observational registry of stroke treated with EVT in France. Patients undergoing EVT for acute BAO from January 2014 to May 2019 successfully treated within 8 hours from onset were included. Predictors of 90-day poor outcome (modified Rankin Scale (mRS) 4–6) were researched within patients with successful (modified Thrombolysis In Cerebral Infarction (mTICI 2b-3)) and excellent (mTICI 2c-3) reperfusion.ResultsAmong 242 patients treated within 8 hours, successful reperfusion was achieved in 195 (80.5%) and excellent reperfusion in 120 (49.5%). Poor outcome was observed in 107 (54.8%) and 60 (50%) patients, respectively. In patients with successful early reperfusion, age, higher initial National Institutes of Health Stroke Scale (NIHSS) score, lower posterior circulation Alberta Stroke Programme Early CT Score (pc-ASPECTS), and absence of prior intravenous thrombolysis were independent predictors of poor outcome. The only treatment factor with an independent predictive value was first-pass mTICI 2b-3 reperfusion (adjusted OR 0.13, 95% CI 0.05 to 0.37, p<0.001). In patients with excellent early reperfusion, independent predictors were age, initial NIHSS score, first-pass mTICI 2c-3 reperfusion, and hemorrhagic transformation on post-interventional imaging.ConclusionsEarly successful reperfusion with EVT occurred in 80.5% of patients, and the only treatment-related factor predictive of clinical outcome was first pass mTICI 2b-3 reperfusion. Further research is warranted to identify the optimal techniques and devices associated with first pass reperfusion in the posterior circulation.
Collapse
Affiliation(s)
- Raoul Pop
- Interventional Neuroradiology, University Hospitals Strasbourg, Strasbourg, France
- Interventional Radiology, Institut de Chirurgie Guidée par l'Image, Strasbourg, France
- University of Strasbourg, INSERM UMR-S1255, Strasbourg, France
| | | | - Caroline Arquizan
- Neurology, Hôpital Gui de Chauliac, Montpellier, Languedoc-Roussillon, France
| | - Mahmoud Elhorany
- Interventional Neuroradiology, Hopital Universitaire Pitie Salpetriere, Paris, France
| | - Olivier Naggara
- Radiology, Saint Anne Hospital Centre, Paris, Île-de-France, France
| | - Jean Darcourt
- Radiology, Hôpital Purpan, Toulouse, Midi-Pyrénées, France
| | - Frédéric Clarençon
- Sorbonne Universite, Paris, Île-de-France, France
- Neuroradiology, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France
| | - Sébastien Richard
- Neurology Stroke Unit, University Hospital Centre Nancy, Nancy, France
| | - Gaultier Marnat
- Interventional and Diagnostic Neuroradiology, University Hospital Centre Bordeaux, Bordeaux, Aquitaine, France
| | | | | | - Cyril Dargazanli
- Neuroradiology, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France
| | - Raphaël Blanc
- Departement of interventional neuroradiology, Fondation Rothschild, Paris, Île-de-France, France
| | - Bertrand Lapergue
- Neurology, Hopital Foch, Suresnes, Île-de-France, France
- Université de Versailles Saint-Quentin-en-Yvelines, Versailles, Île-de-France, France
| | - Arturo Consoli
- Diagnostic and Interventional Neuroradiology, Hospital Foch, Suresnes, France
- Interventional Neurovascular Unit, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
| | | | | | - Jildaz Caroff
- Department of Interventional Neuroradiology - NEURI Brain Vascular Center, Bicêtre Hospital, APHP, Le Kremlin Bicêtre, France
| | | | - Marion Boulanger
- Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France
| | - Maxime Gauberti
- Neuroradiology, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France
| | - Aymeric Rouchaud
- Interventional neuroradiology, Centre Hospitalier Universitaire de Limoges, Limoges, France
- CNRS, XLIM, UMR 7252, Limoges University, Limoges, Nouvelle-Aquitaine, France
| | - Francisco Macian
- Department of Neurology, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France
| | - Charlotte Rosso
- Urgences cérébro-vasculaires, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France
| | - Guillaume Turc
- Neurology, Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences, Paris, Île-de-France, France
| | | | | | - Anthony Le Bras
- Department of Radiology, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France
- CHU Rennes Service de radiologie et d'imagerie médicale, Rennes, France
| | - Sarah Evain
- Department of Neurology, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France
| | - Valerie Wolff
- Neurology, University Hospitals Strasbourg, Strasbourg, Alsace, France
| | - Serge Timsit
- Department of Neurology, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France
| | | | - Frédéric Bourdain
- Department of Neurology, Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France
| | - Louis Veunac
- Department of Neuroradiolology, Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France
| | - Chrysanthi Papagiannaki
- Interventional Neuroradiology, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France
| | - Benjamin Gory
- Department of Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France
- IADI, INSERM U1254, Universite de Lorraine, Nancy, Lorraine, France
| |
Collapse
|
25
|
de Graaf L, Boulanger M, Bureau M, Bouvier G, Meryet-Figuiere M, Tual S, Lebailly P, Baldi I. Occupational pesticide exposure, cancer and chronic neurological disorders: A systematic review of epidemiological studies in greenspace workers. Environ Res 2022; 203:111822. [PMID: 34352232 DOI: 10.1016/j.envres.2021.111822] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 07/29/2021] [Accepted: 07/30/2021] [Indexed: 06/13/2023]
Abstract
CONTEXT The greenspace sector includes a broad range of occupations: gardeners, landscapers, municipal workers, maintenance operators of public facilities, golf-course employees and other sports facilities, horticulturists, plant and tree nursery workers etc. The health impact of occupational pesticide exposure has mainly been studied among farmers. Other professionals such as greenspace workers are also extremely exposed, presenting specific exposure features (practices, types of pesticide used). The aim of this review was to summarize epidemiological literature that examine the relationship between pesticide exposure and the risk of cancer and long-term health effects in greenspace workers. METHOD Six main groups of greenspace workers were identified and examined through a systematic literature review based on PubMed and Scopus. The studies were then grouped according to their design, health outcomes and the type of population studied. RESULTS Forty-four articles were selected among the 1679 identified. Fifteen studies were conducted exclusively among greenspace workers, while ten also studied these workers with other pesticide applicators. Six were cohorts from the general population in which greenspace workers were identified. Elevated risks were found in several studies for leukaemia, soft-tissue sarcoma, multiple myeloma, non-Hodgkin lymphoma and Parkinson's disease. DISCUSSION The majority of studies used rough parameters for defining exposure such as job titles which could lead to the misclassification of exposure, with the risk of false or positive negative conclusions. Health outcomes were mainly collected through registries or death certificates, and information regarding potential confounders was often missing. CONCLUSION The review identified only 15 studies conducted exclusively among greenspace workers. Elevated risk was found for several sites of cancer and Parkinson's diseases. Further epidemiological research is needed, conducted specifically on these workers, to better characterize this population, its exposure to pesticides and the related health effects.
Collapse
Affiliation(s)
- L de Graaf
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France.
| | - M Boulanger
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - M Bureau
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - G Bouvier
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - M Meryet-Figuiere
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - S Tual
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - P Lebailly
- INSERM U1086 Anticipe, 3 avenue Général Harris, 14000, Caen, France; Centre de Lutte contre le Cancer François Baclesse, 3 avenue Général Harris, 14000, Caen, France; Université de Caen Normandie, Esplanade de la Paix, 14000, Caen, France
| | - I Baldi
- ISPED, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France; INSERM U1219 Epicene, 146 rue Léo Saignat, 33076, Bordeaux, France; Service Santé Travail Environnement, CHU de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France
| |
Collapse
|
26
|
Happi Ngankou E, Gory B, Marnat G, Richard S, Bourcier R, Sibon I, Dargazanli C, Arquizan C, Maïer B, Blanc R, Lapergue B, Consoli A, Vannier S, Spelle L, Denier C, Boulanger M, Gauberti M, Saleme S, Macian F, Clarençon F, Rosso C, Naggara O, Turc G, Ozkul-Wermester O, Papagiannaki C, Viguier A, Cognard C, Lebras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, Eugène F, Finitsis S. Thrombectomy Complications in Large Vessel Occlusions: Incidence, Predictors, and Clinical Impact in the ETIS Registry. Stroke 2021; 52:e764-e768. [PMID: 34706564 DOI: 10.1161/strokeaha.121.034865] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Procedural complications in thrombectomy for large vessel occlusions of the anterior circulation are not well described. We investigated the incidence, risk factors, and clinical implications of thrombectomy complications in daily clinical practice. METHODS We used data from the ongoing prospective multicenter observational Endovascular Treatment in Ischemic Stroke Registry in France. The present study is a retrospective analysis of 4029 stroke patients with anterior large vessel occlusions treated with thrombectomy between January 2015 and May 2020 in 18 centers. We systematically collected procedural data, incidence of embolic complications, perforations and dissections, clinical outcome at 90 days, and hemorrhagic complications. RESULTS Procedural complications occurred in 7.99% (95% CI, 7.17%-8.87%), and embolus to a new territory (ENT) was the most frequent (5.2%). Predictors of ENTs were terminal carotid/tandem occlusion (odds ratio [OR], 5 [95% CI, 2.03-12.31]; P<0.001) and an increased total number of passes (OR, 1.22 [95% CI, 1.05-1.41]; P=0.006). ENTs were associated to worse clinical outcomes (90-day modified Rankin Scale score, 0-2; adjusted OR, 0.4 [95% CI, 0.25-0.63]; P<0.001), increased mortality (adjusted OR, 1.74 [95% CI, 1.2-2.53]; P<0.001), and symptomatic intracerebral hemorrhage (adjusted OR, 1.87 [95% CI, 1.15-3.03]; P=0.011). Perforations occurred in 1.69% (95% CI, 1.31%-2.13%). Predictors of perforations were terminal carotid/tandem occlusions (39.7% versus 27.6%; P=0.028). 40.7% of patients died at 90 days, and the overall rate of poor outcome was 74.6% in case of perforation. Dissections occurred in 1.46% (95% CI, 1.11%-1.88%) and were more common in younger patients (median age, 64.2 versus 70.2 years; P=0.002). Dissections did not affect the clinical outcome at 90 days. Besides dissection, complications were independent of the thrombectomy technique. CONCLUSIONS Thrombectomy complication rate is not negligible, and ENTs were the most frequent. ENTs and perforations were associated with disability and mortality, and terminal carotid/tandem occlusions were a risk factor. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03776877.
Collapse
Affiliation(s)
- Emmanuel Happi Ngankou
- Department of Diagnostic and Therapeutic Neuroradiology (E.H.N., B.G.), Université de Lorraine, CHRU-Nancy, France
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology (E.H.N., B.G.), Université de Lorraine, CHRU-Nancy, France.,IADI, INSERM U1254, Université de Lorraine, Nancy, France (B.G.)
| | - Gaultier Marnat
- Department of Diagnostic and Interventional Neuroradiology, University Hospital of Bordeaux, France (G.M.)
| | - Sébastien Richard
- Department of Neurology, Stroke Unit (S.R.), Université de Lorraine, CHRU-Nancy, France.,CIC-P 1433, INSERM U1116, CHRU-Nancy, France (S.R.)
| | - Romain Bourcier
- Department of Neuroradiology, University Hospital of Nantes, France (R.B.)
| | - Igor Sibon
- Department of Neurology, Stroke Center, University Hospital of Bordeaux, France (I.S.)
| | - Cyril Dargazanli
- Department of Interventional Neuroradiology (C.D.), CHRU Gui de Chauliac, Montpellier, France
| | - Caroline Arquizan
- Department of Neurology (C.A.), CHRU Gui de Chauliac, Montpellier, France
| | - Benjamin Maïer
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France (B.M., R.B.)
| | - Raphaël Blanc
- Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France (B.M., R.B.)
| | - Bertrand Lapergue
- Department of Neurology (B.L.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Arturo Consoli
- Department of Diagnostic and Interventional Neuroradiology (A.C.), Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Stéphane Vannier
- Department of Neurology, Stroke Unit (S.V.), University Hospital of Rennes, France
| | - Laurent Spelle
- Neuroradiolology (L.S.), CHU Kremlin Bicêtre, Paris, France
| | - Christian Denier
- Departments of Neurology (C.D.), CHU Kremlin Bicêtre, Paris, France
| | | | | | - Suzana Saleme
- Department of Interventional Neuroradiology (S.S.), CHU Limoges, France
| | | | | | - Charlotte Rosso
- Departments of Neurology (C.R.), CHU Pitié-Salpétrière, Paris, France
| | | | - Guillaume Turc
- Departments of Neurology (G.T.), Hôpital Saint Anne, Paris, France
| | | | | | - Alain Viguier
- Departments of Neurology (A.V.), CHU Toulouse, France
| | | | - Anthony Lebras
- Departments of Neurology (A.L.), CH Bretagne Atlantique, Vannes, France
| | - Sarah Evain
- Neuroradiolology (S.E.), CH Bretagne Atlantique, Vannes, France
| | - Valérie Wolff
- Departments of Neurology (V.W.), CHU Strasbourg, France
| | - Raoul Pop
- Neuroradiolology (R.P.), CHU Strasbourg, France
| | - Serge Timsit
- Departments of Neurology (S.T.), CHU Brest, France
| | | | | | - Louis Veunac
- Neuroradiolology (L.V.), CH Côte Basque, Bayonne, France
| | - François Eugène
- Department of Neuroradiology (F.E.), University Hospital of Rennes, France
| | | | | |
Collapse
|
27
|
Boulanger M. [Risk of myocardial infarction after ischemic stroke]. Rev Prat 2021; 71:830-832. [PMID: 35147333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- Marion Boulanger
- Normandie Université, CHU Caen Normandie, service de neurologie, INSERM U1237, Caen, France
| |
Collapse
|
28
|
Boulanger M, Nunes JC, Chourak H, Largent A, Tahri S, Acosta O, De Crevoisier R, Lafond C, Barateau A. Deep learning methods to generate synthetic CT from MRI in radiotherapy: A literature review. Phys Med 2021; 89:265-281. [PMID: 34474325 DOI: 10.1016/j.ejmp.2021.07.027] [Citation(s) in RCA: 59] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 07/15/2021] [Accepted: 07/19/2021] [Indexed: 01/04/2023] Open
Abstract
PURPOSE In radiotherapy, MRI is used for target volume and organs-at-risk delineation for its superior soft-tissue contrast as compared to CT imaging. However, MRI does not provide the electron density of tissue necessary for dose calculation. Several methods of synthetic-CT (sCT) generation from MRI data have been developed for radiotherapy dose calculation. This work reviewed deep learning (DL) sCT generation methods and their associated image and dose evaluation, in the context of MRI-based dose calculation. METHODS We searched the PubMed and ScienceDirect electronic databases from January 2010 to March 2021. For each paper, several items were screened and compiled in figures and tables. RESULTS This review included 57 studies. The DL methods were either generator-only based (45% of the reviewed studies), or generative adversarial network (GAN) architecture and its variants (55% of the reviewed studies). The brain and pelvis were the most commonly investigated anatomical localizations (39% and 28% of the reviewed studies, respectively), and more rarely, the head-and-neck (H&N) (15%), abdomen (10%), liver (5%) or breast (3%). All the studies performed an image evaluation of sCTs with a diversity of metrics, with only 36 studies performing dosimetric evaluations of sCT. CONCLUSIONS The median mean absolute errors were around 76 HU for the brain and H&N sCTs and 40 HU for the pelvis sCTs. For the brain, the mean dose difference between the sCT and the reference CT was <2%. For the H&N and pelvis, the mean dose difference was below 1% in most of the studies. Recent GAN architectures have advantages compared to generator-only, but no superiority was found in term of image or dose sCT uncertainties. Key challenges of DL-based sCT generation methods from MRI in radiotherapy is the management of movement for abdominal and thoracic localizations, the standardization of sCT evaluation, and the investigation of multicenter impacts.
Collapse
Affiliation(s)
- M Boulanger
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| | - Jean-Claude Nunes
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France.
| | - H Chourak
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France; CSIRO Australian e-Health Research Centre, Herston, Queensland, Australia
| | - A Largent
- Developing Brain Institute, Department of Diagnostic Imaging and Radiology, Children's National Hospital, Washington, DC, USA
| | - S Tahri
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| | - O Acosta
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| | - R De Crevoisier
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| | - C Lafond
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| | - A Barateau
- Univ. Rennes 1, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, F-35000 Rennes, France
| |
Collapse
|
29
|
Hostettler IC, Wilson D, Fiebelkorn CA, Aum D, Ameriso SF, Eberbach F, Beitzke M, Kleinig T, Phan T, Marchina S, Schneckenburger R, Carmona-Iragui M, Charidimou A, Mourand I, Parreira S, Ambler G, Jäger HR, Singhal S, Ly J, Ma H, Touzé E, Geraldes R, Fonseca AC, Melo T, Labauge P, Lefèvre PH, Viswanathan A, Greenberg SM, Fortea J, Apoil M, Boulanger M, Viader F, Kumar S, Srikanth V, Khurram A, Fazekas F, Bruno V, Zipfel GJ, Refai D, Rabinstein A, Graff-Radford J, Werring DJ. Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. J Neurol 2021; 269:1427-1438. [PMID: 34272978 PMCID: PMC8857171 DOI: 10.1007/s00415-021-10706-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 07/06/2021] [Accepted: 07/09/2021] [Indexed: 11/29/2022]
Abstract
Objective To investigate the frequency, time-course and predictors of intracerebral haemorrhage (ICH), recurrent convexity subarachnoid haemorrhage (cSAH), and ischemic stroke after cSAH associated with cerebral amyloid angiopathy (CAA). Methods We performed a systematic review and international individual patient-data pooled analysis in patients with cSAH associated with probable or possible CAA diagnosed on baseline MRI using the modified Boston criteria. We used Cox proportional hazards models with a frailty term to account for between-cohort differences. Results We included 190 patients (mean age 74.5 years; 45.3% female) from 13 centers with 385 patient-years of follow-up (median 1.4 years). The risks of each outcome (per patient-year) were: ICH 13.2% (95% CI 9.9–17.4); recurrent cSAH 11.1% (95% CI 7.9–15.2); combined ICH, cSAH, or both 21.4% (95% CI 16.7–26.9), ischemic stroke 5.1% (95% CI 3.1–8) and death 8.3% (95% CI 5.6–11.8). In multivariable models, there is evidence that patients with probable CAA (compared to possible CAA) had a higher risk of ICH (HR 8.45, 95% CI 1.13–75.5, p = 0.02) and cSAH (HR 3.66, 95% CI 0.84–15.9, p = 0.08) but not ischemic stroke (HR 0.56, 95% CI 0.17–1.82, p = 0.33) or mortality (HR 0.54, 95% CI 0.16–1.78, p = 0.31). Conclusions Patients with cSAH associated with probable or possible CAA have high risk of future ICH and recurrent cSAH. Convexity SAH associated with probable (vs possible) CAA is associated with increased risk of ICH, and cSAH but not ischemic stroke. Our data provide precise risk estimates for key vascular events after cSAH associated with CAA which can inform management decisions. Supplementary Information The online version contains supplementary material available at 10.1007/s00415-021-10706-3.
Collapse
Affiliation(s)
- Isabel Charlotte Hostettler
- Stroke Research Centre, University College London, National Hospital of Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, WC1N, UK
| | - Duncan Wilson
- Stroke Research Centre, University College London, National Hospital of Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, WC1N, UK
| | | | - Diane Aum
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA
| | | | | | - Markus Beitzke
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - Timothy Kleinig
- Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia
| | - Thanh Phan
- Department of Neurology, Monash Health and Stroke and Ageing Research Group, Melbourne, Australia.,Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
| | - Sarah Marchina
- Department of Neurology, Stroke Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | | | - Maria Carmona-Iragui
- Memory Unit, Department of Neurology, Hospital de la Santa Creu I Sant Pau, Institut Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Andreas Charidimou
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Isabelle Mourand
- Department of Neurology, CHU de Montpellier, Hôpital Gui-de-Chauliac, Montpellier, France
| | - Sara Parreira
- Stroke Unit, Department of Neuroscience, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal
| | - Gareth Ambler
- Department of Statistical Science, UCL, London, WC1E 6BT, UK
| | - Hans Rolf Jäger
- Neuroradiological Academic Unit, Department of Brain Repair & Rehabilitation, University College London, Institute of Neurology, London, UK
| | - Shaloo Singhal
- Department of Neurology, Monash Health and Stroke and Ageing Research Group, Melbourne, Australia.,Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
| | - John Ly
- Department of Neurology, Monash Health and Stroke and Ageing Research Group, Melbourne, Australia.,Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
| | - Henry Ma
- Department of Neurology, Monash Health and Stroke and Ageing Research Group, Melbourne, Australia.,Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
| | - Emmanuel Touzé
- Normandy University, UNICAEN, INSERM U1237, Caen, France
| | - Ruth Geraldes
- Nuffield Department of Clinical Neurosciences, Oxford University Hospitals, Oxford, UK.,Neurology department, Frimley Health Foundation Trust, Camberley, UK
| | - Ana Catarina Fonseca
- Stroke Unit, Department of Neuroscience, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal
| | - Teresa Melo
- Stroke Unit, Department of Neuroscience, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal
| | - Pierre Labauge
- Department of Neurology, CHU de Montpellier, Hôpital Gui-de-Chauliac, Montpellier, France
| | - Pierre-Henry Lefèvre
- Department of Neuroradiology, CHU de Montpellier, Hôpital Gui-de-Chauliac, Montpellier, France
| | - Anand Viswanathan
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Steven Mark Greenberg
- J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Juan Fortea
- Memory Unit, Department of Neurology, Hospital de la Santa Creu I Sant Pau, Institut Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Marion Apoil
- Department of Neurology, CHU Caen Normandie, Caen, France
| | - Marion Boulanger
- Department of Neurology, CHU Caen Normandie, Caen, France.,Normandy University, UNICAEN, INSERM U1237, Caen, France
| | - Fausto Viader
- Department of Neurology, CHU Caen Normandie, Caen, France
| | - Sandeep Kumar
- Department of Neurology, Stroke Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Velandai Srikanth
- Department of Neurology, Monash Health and Stroke and Ageing Research Group, Melbourne, Australia.,Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
| | - Ashan Khurram
- Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia
| | - Franz Fazekas
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - Veronica Bruno
- Institute for Neurological Research, Fleni, Buenos Aires, Argentina
| | - Gregory Joseph Zipfel
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA
| | - Daniel Refai
- Department of Neurosurgery, Emory University, Atlanta, GA, USA
| | | | | | - David John Werring
- Stroke Research Centre, University College London, National Hospital of Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, WC1N, UK.
| |
Collapse
|
30
|
Anadani M, Finitsis S, Clarençon F, Richard S, Marnat G, Bourcier R, Sibon I, Dargazanli C, Arquizan C, Blanc R, Lapergue B, Consoli A, Eugene F, Vannier S, Spelle L, Denier C, Boulanger M, Gauberti M, Liebeskind DS, de Havenon A, Saleme S, Macian F, Rosso C, Naggara O, Turc G, Ozkul-Wermester O, Papagiannaki C, Viguier A, Cognard C, Le Bras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, Maier B, Gory B. Collateral status reperfusion and outcomes after endovascular therapy: insight from the Endovascular Treatment in Ischemic Stroke (ETIS) Registry. J Neurointerv Surg 2021; 14:551-557. [PMID: 34140288 DOI: 10.1136/neurintsurg-2021-017553] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Accepted: 05/31/2021] [Indexed: 01/13/2023]
Abstract
BACKGROUND Studies have suggested that collateral status modifies the effect of successful reperfusion on functional outcome after endovascular therapy (EVT). We aimed to assess the association between collateral status and EVT outcomes and to investigate whether collateral status modified the effect of successful reperfusion on EVT outcomes. METHODS We used data from the ongoing, prospective, multicenter Endovascular Treatment in Ischemic Stroke (ETIS) Registry. Collaterals were graded according to the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) guidelines. Patients were divided into two groups based on angiographic collateral status: poor (grade 0-2) versus good (grade 3-4) collaterals. RESULTS Among 2020 patients included in the study, 959 (47%) had good collaterals. Good collaterals were associated with favorable outcome (90-day modified Rankin Scale (mRS) 0-2) (OR 1.5, 95% CI 1.19 to 1.88). Probability of good outcome decreased with increased time from onset to reperfusion in both good and poor collateral groups. Successful reperfusion was associated with higher odds of favorable outcome in good collaterals (OR 6.01, 95% CI 3.27 to 11.04) and poor collaterals (OR 5.65, 95% CI 3.32 to 9.63) with no significant interaction. Similarly, successful reperfusion was associated with higher odds of excellent outcome (90-day mRS 0-1) and lower odds of mortality in both groups with no significant interaction. The benefit of successful reperfusion decreased with time from onset in both groups, but the curve was steeper in the poor collateral group. CONCLUSIONS Collateral status predicted functional outcome after EVT. However, collateral status on the pretreatment angiogram did not decrease the clinical benefit of successful reperfusion.
Collapse
Affiliation(s)
- Mohammad Anadani
- Department of Neurology, Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, USA .,Neurology, Neurosurgery, Medical University of South Carolina,College of Medicine, Charleston, South Carolina, USA
| | - Stephanos Finitsis
- Neuroradiolology, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
| | - Frédéric Clarençon
- Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France.,Neuroradiology, Sorbonne Université, Paris, Paris, France
| | - Sébastien Richard
- Neurology Stroke Unit, University Hospital Centre Nancy, Nancy, France
| | - Gaultier Marnat
- Interventional and Diagnostic Neuroradiology, Bordeaux University Hospital, Bordeaux, France
| | - Romain Bourcier
- Neuroradiology, University Hospital of Nantes, Nantes, France
| | - Igor Sibon
- Neuroradiology, CHU de Bordeaux, Bordeaux, France
| | - Cyril Dargazanli
- Neuroradiology, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France
| | | | - Raphael Blanc
- Interventional Neuroradiology, Fondation Rothschild, Paris, Île-de-France, France
| | | | - Arturo Consoli
- Diagnostic and Interventional Neuroradiology, Hospital Foch, Suresnes, France.,Interventional Neurovascular Unit, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
| | | | | | - Laurent Spelle
- Department of Neuroradiolology, CHU Kremlin Bicêtre, Paris, France
| | | | | | | | - David S Liebeskind
- Neurology, University of California, Los Angeles, Los Angeles, California, USA
| | - Adam de Havenon
- Department of Neurology, University of Utah, Salt Lake City, Utah, USA
| | | | | | - Charlotte Rosso
- Department of Neurology, CHU Pitié-Salpétrière, Paris, France
| | | | - Guillaume Turc
- Neurology, Stroke Unit, Hôpital Saint Anne, Paris, France
| | | | | | - Alain Viguier
- Department of Neurology, CHU Toulouse, Toulouse, France
| | - Christophe Cognard
- Diagnostic and Therapeutic Neuroradiology, Hôpital Purpan, Toulouse, France
| | - Anthony Le Bras
- Department of Radiology, CH Bretagne Atlantique, Vannes, France.,Department of Neurology, CHU Rennes Service de radiologie et d'imagerie médicale, Rennes, France
| | - Sarah Evain
- Department of Neurology, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France
| | - Valerie Wolff
- Stroke unit, Strasbourg University Hospitals, Strasbourg, France
| | - Raoul Pop
- Department of Neuroradiolology, CHU Strasbourg, Strasbourg, France
| | - Serge Timsit
- Department of Neurology, CHU Brest, Brest, France
| | | | | | - Louis Veunac
- Department of Neuroradiolology, CH Côte Basque, Bayonne, France
| | - Benjamin Maier
- Interventional Neuroradiology, Adolphe de Rothschild Ophthalmological Foundation, Paris, France
| | - Benjamin Gory
- Diagnostic and Interventional Neuroradiology, Centre Hospitalier Universitaire de Nancy, Nancy, France
| | | |
Collapse
|
31
|
Muszynski P, Anadani M, Richard S, Marnat G, Bourcier R, Sibon I, Dargazanli C, Arquizan C, Maïer B, Blanc R, Lapergue B, Consoli A, Eugene F, Vannier S, Spelle L, Denier C, Boulanger M, Gauberti M, Saleme S, Macian F, Clarençon F, Rosso C, Naggara O, Turc G, Ozkul-Wermester O, Papagiannaki C, Viguier A, Cognard C, Le Bras A, Evain S, Wolff V, Pop R, Timsit S, Gentric JC, Bourdain F, Veunac L, Gory B, Finitsis SN. Endovascular reperfusion of M2 occlusions in acute ischemic stroke reduced disability and mortality: ETIS Registry results. J Neurointerv Surg 2021; 14:neurintsurg-2021-017380. [PMID: 34045317 DOI: 10.1136/neurintsurg-2021-017380] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Accepted: 05/13/2021] [Indexed: 11/04/2022]
Abstract
BACKGROUND The predictors of successful reperfusion and the effect of reperfusion after endovascular treatment (EVT) for M2 occlusions have not been well studied. We aimed to identify predictors of successful reperfusion and the effect of reperfusion on outcomes of EVT for M2 occlusions in current practice. METHODS Patients with acute ischemic stroke due to isolated M2 occlusions who were enrolled in the prospective multicenter Endovascular Treatment in Ischemic Stroke (ETIS) Registry in France between January 2015 and March 2020 were included. The primary outcome was a favorable outcome, defined as modified Rankin Scale (mRS) score of 0-2 at 90 days. Successful reperfusion was defined as an improvement of ≥1 points in the modified Thrombolysis In Cerebral Infarction score between the first and the last intracranial angiogram. RESULTS A total of 458 patients were included (median National Institutes of Health Stroke Scale (NIHSS) score 14; 61.4% received prior intravenous thrombolysis). Compared with the non-reperfused patients, reperfused patients had an increased rate of excellent outcome (OR 2.3, 95% CI 0.98 to 5.36; p=0.053), favorable outcome (OR 2.79, 95% CI 1.31 to 5.93; p=0.007), and reduced 90-day mortality (OR 0.39, 95% CI 0.19 to 0.79; p<0.01). Admission NIHSS score was the only predictor of successful reperfusion. First-line strategy was not a predictor of successful reperfusion or favorable outcome, but the use of a stent retriever, alone or with an aspiration catheter, was associated with higher rates of procedural complications and 90-day mortality. CONCLUSIONS Successful reperfusion of M2 occlusions reduced disability and mortality. However, safety is a concern, especially if the procedure failed.
Collapse
Affiliation(s)
- Patricio Muszynski
- Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, CHRU-Nancy, Nancy, France
| | - Mohammad Anadani
- Washington University School of Medicine in St Louis, St Louis, Missouri, USA.,Neurology, Medical University of South Carolina - College of Medicine, Charleston, South Carolina, USA
| | - Sébastien Richard
- Neurology, Stroke Unit, Université de Lorraine, CHRU-Nancy, Nancy, France
| | - Gaultier Marnat
- Interventional and Diagnostic Neuroradiology, CHU Bordeaux, Bordeaux, France
| | - Romain Bourcier
- Neuroradiology, University Hospital of Nantes, Nantes, France
| | - Igor Sibon
- Neurology, Stroke Unit, CHU Bordeaux, Bordeaux, France
| | | | | | - Benjamin Maïer
- Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Raphaël Blanc
- Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | | | - Arturo Consoli
- Diagnostic and Therapeutic Neuroradiology, Foch Hospital, Suresnes, France
| | | | | | - Laurent Spelle
- Interventional Neuroradiolology, CHU Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | | | | | | | - Frédéric Clarençon
- Sorbonne Université, Paris, France.,Neuroradiology, CHU Pitié-Salpêtrière, Paris, France
| | - Charlotte Rosso
- Neurology, Stroke Unit, CHU Pitié-Salpêtrière, Paris, France
| | | | - Guillaume Turc
- Neurology, Stroke Unit, Hôpital Saint Anne, Paris, France
| | | | | | - Alain Viguier
- Neurology, Stroke Unit, CHU Toulouse, Toulouse, France
| | - Christophe Cognard
- Diagnostic and Therapeutic Neuroradiology, CHU Toulouse, Toulouse, France
| | | | - Sarah Evain
- Neurology, Stroke Unit, CH Bretagne Atlantique, Vannes, France
| | | | - Raoul Pop
- Interventional Neuroradiolology, CHU Strasbourg, Strasbourg, France
| | - Serge Timsit
- Neurology, Stroke Unit, CHU Brest, Brest, France
| | | | | | | | - Benjamin Gory
- Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, CHRU-Nancy, Nancy, France .,IADI, INSERM U1254, Université de Lorraine, Nancy, France
| | - Stephanos Nikolaos Finitsis
- Neuroradiolology, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece.,Radiology, Centre Hospitalier de L'Universite de Montreal, Montreal, Quebec, Canada
| | | |
Collapse
|
32
|
Arnaud C, Boulanger M, Lorthioir A, Amar L, Azarine A, Boyer L, Chatellier G, Di Monaco S, Jeunemaitre X, Kastler A, Mousseaux E, Oppenheim C, Thony F, Persu A, Olin JW, Azizi M, Touzé E. Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia. J Am Heart Assoc 2021; 10:e018311. [PMID: 33998257 PMCID: PMC8483547 DOI: 10.1161/jaha.120.018311] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Background Cervical artery dissection (CeAD) is a frequent manifestation of fibromuscular dysplasia (FMD). However, risk factors for CeAD are unknown. We investigated factors associated with CeAD in the ARCADIA (Assessment of Renal and Cervical Artery Dysplasia) registry. Methods and Results The ARCADIA registry includes women or men aged ≥18 years, with a diagnosis of renal, cervical, or intracranial artery FMD, who were prospectively recruited at 16 university hospitals in France and Belgium. Diagnosis of acute or past CeAD at inclusion was established on imaging according to standard diagnostic criteria. Associations between potential determinants and CeAD were assessed by logistic regression analyses. Among 469 patients (75 men) with FMD, 65 (13.9%) had CeAD. Patients with CeAD were younger, more likely to be men, have a history of migraine, and less likely to have a history of hypertension than patients without CeAD. In the multivariable analysis, male sex (odds ratio [OR], 2.66; 95% CI, 1.34-5.25), history of migraine (OR, 1.90; 95% CI, 1.06-3.39), age ≥50 years (OR, 0.41; 95% CI, 0.23-0.73), history of hypertension (OR, 0.35; 95% CI, 0.20-0.64), and involvement of ≥3 vascular beds (OR, 2.49; 95% CI, 1.15-5.40) were significantly associated with CeAD. To validate the association between CeAD and sex, we performed a systematic review. We collected additional data on sex from 2 published studies and unpublished data from the US Registry for Fibromuscular Dysplasia and the European/International FMD Registry. In the pooled analysis (289 CeAD, 1933 patients), male sex was significantly associated with CeAD (OR, 2.04; 95% CI, 1.41-2.95; I2=0%). Conclusions In patients with FMD, male sex and multisite involvement are associated with CeAD, in addition to other previously known risk factors. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02884141.
Collapse
Affiliation(s)
- Charlotte Arnaud
- Department of Neurology Inserm U1237 Normandie UniversitéUniversité Caen NormandieCHU Caen Normandie Caen France
| | - Marion Boulanger
- Department of Neurology Inserm U1237 Normandie UniversitéUniversité Caen NormandieCHU Caen Normandie Caen France
| | - Aurélien Lorthioir
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France
| | - Laurence Amar
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France
| | - Arshid Azarine
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France.,Department of Radiology Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France
| | - Louis Boyer
- Department of Radiology CHU Clermont-Ferrand, Hopital Gabriel Montpied Clermont Ferrand France
| | - Gilles Chatellier
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France.,Clinical Research Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges Pompidou Paris France
| | - Silvia Di Monaco
- Division of Internal Medicine and Hypertension Unit Department of Medical Sciences University of Turin Italy.,Pole of Cardiovascular Research Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain Brussels Belgium.,Division of Cardiology Cliniques Universitaires Saint-LucUniversité Catholique de Louvain Brussels Belgium
| | - Xavier Jeunemaitre
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France.,Department of Genetics Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France
| | | | - Elie Mousseaux
- Department of Radiology Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France
| | - Catherine Oppenheim
- Department of Radiology and INSERM U1266 GHU Paris Psychiatry and Neurosciences Université de Paris France
| | | | - Alexandre Persu
- Pole of Cardiovascular Research Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain Brussels Belgium.,Division of Cardiology Cliniques Universitaires Saint-LucUniversité Catholique de Louvain Brussels Belgium
| | - Jeffrey W Olin
- Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health Icahn School of Medicine at Mount Sinai New York NY
| | - Michel Azizi
- Hypertension Unit Assistance Publique-Hôpitaux de Paris Hôpital Européen Georges PompidouUniversité de Paris France.,INSERM CIC1418 Paris France
| | - Emmanuel Touzé
- Department of Neurology Inserm U1237 Normandie UniversitéUniversité Caen NormandieCHU Caen Normandie Caen France
| | | |
Collapse
|
33
|
Persu A, Dobrowolski P, Gornik HL, Olin JW, Adlam D, Azizi M, Boutouyrie P, Bruno RM, Boulanger M, Demoulin JB, Ganesh SK, Guzik T, Januszewicz M, Kovacic JC, Kruk M, Leeuw DP, Loeys B, Pappaccogli M, Perik M, Touzé E, Van der Niepen P, Van Twist DJL, Warchoł-Celińska E, Prejbisz A, Januszewicz A. Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovasc Res 2021; 118:65-83. [PMID: 33739371 DOI: 10.1093/cvr/cvab086] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Accepted: 03/17/2021] [Indexed: 12/11/2022] Open
Abstract
Fibromuscular dysplasia (FMD) is a non-atherosclerotic vascular disease that may involve medium-sized muscular arteries throughout the body. The majority of FMD patients are women. Although a variety of genetic, mechanical, and hormonal factors play a role in the pathogenesis of FMD, overall, its cause remains poorly understood. It is probable that the pathogenesis of FMD is linked to a combination of genetic and environmental factors. Extensive studies have correlated the arterial lesions of FMD to histopathological findings of arterial fibrosis, cellular hyperplasia, and distortion of the abnormal architecture of the arterial wall. More recently, the vascular phenotype of lesions associated with FMD has been expanded to include arterial aneurysms, dissections, and tortuosity. However, in the absence of a string of beads or focal stenosis, these lesions do not suffice to establish the diagnosis. While FMD most commonly involves renal and cerebrovascular arteries, involvement of most arteries throughout the body has been reported. Increasing evidence highlights that FMD is a systemic arterial disease and that subclinical alterations can be found in non-affected arterial segments. Recent significant progress in FMD-related research which has led to improved understandings of the disease's clinical manifestations, natural history, epidemiology, and genetics. Ongoing work continues to focus on FMD genetics and proteomics, physiological effects of FMD on cardiovascular structure and function, and novel imaging modalities and blood-based biomarkers that can be used to identify subclinical FMD. It is also hoped that the next decade will bring the development of multi-centred and potentially international clinical trials to provide comparative effectiveness data to inform the optimal management of patients with FMD.
Collapse
Affiliation(s)
- Alexandre Persu
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Piotr Dobrowolski
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
| | - Heather L Gornik
- University Hospitals Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA
| | - Jeffrey W Olin
- Zena and Michael A. Wiener Cardiovascular Institute and Marie-José and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - David Adlam
- Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester University, Leicester, UK
| | - Michel Azizi
- Université de Paris, INSERM CIC1418, Paris, France.,AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE, Paris, France
| | - Pierre Boutouyrie
- Université de Paris, INSERM U970 Team 7, Paris, France.,AP-HP, Hôpital Européen Georges-Pompidou, Pharmacology Department and DMU CARTE, Paris, France
| | - Rosa Maria Bruno
- Université de Paris, INSERM U970 Team 7, Paris, France.,AP-HP, Hôpital Européen Georges-Pompidou, Pharmacology Department and DMU CARTE, Paris, France
| | - Marion Boulanger
- Normandie Université, UNICAEN, Inserm U1237, CHU Caen Normandie, Caen, France
| | | | - Santhi K Ganesh
- Division of Cardiovascular Medicine, Department of Internal Medicine, and Department of Human Genetics University of Michigan, Ann Arbor, Michigan, USA
| | - Tomasz Guzik
- Jagiellonian University, Collegium Medicum, Krakow, Poland.,Institute of Cardiovascular & Medical Sciences BHF Glasgow Cardiovascular Research Centre; Glasgow, UK
| | | | - Jason C Kovacic
- Zena and Michael A. Wiener Cardiovascular Institute and Marie-José and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Victor Chang Cardiac Research Institute, Darlinghurst, Australia, and St. Vincent's Clinical School, University of NSW, Australia
| | - Mariusz Kruk
- Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland
| | - de Peter Leeuw
- Department of Internal Medicine and Gastroenterology, Zuyderland Medical Center, Heerlen, The Netherlands.,Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands.,CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands
| | - Bart Loeys
- Center for Medical Genetics, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium
| | - Marco Pappaccogli
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.,Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Melanie Perik
- Center for Medical Genetics, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium
| | | | - Patricia Van der Niepen
- Department of Nephrology & Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) Brussels, Belgium
| | | | | | - Aleksander Prejbisz
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
| | - Andrzej Januszewicz
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
| |
Collapse
|
34
|
Zhu F, Hossu G, Soudant M, Richard S, Achit H, Beguinet M, Costalat V, Arquizan C, Consoli A, Lapergue B, Rouchaud A, Macian-Montoro F, Biondi A, Moulin T, Marnat G, Sibon I, Paya C, Vannier S, Cognard C, Viguier A, Mazighi M, Obadia M, Hassen WB, Turc G, Clarençon F, Samson Y, Dumas-Duport B, Preterre C, Barbier C, Boulanger M, Janot K, Annan M, Bricout N, Henon H, Soize S, Moulin S, Labeyrie MA, Reiner P, Pop R, Wolff V, Ognard J, Timsit S, Reyre A, Perot C, Papagiannaki C, Triquenot-Bagan A, Bracard S, Anxionnat R, Derelle AL, Tonnelet R, Liao L, Schmitt E, Planel S, Guillemin F, Gory B. Effect of emergent carotid stenting during endovascular therapy for acute anterior circulation stroke patients with tandem occlusion: A multicenter, randomized, clinical trial (TITAN) protocol. Int J Stroke 2020; 16:342-348. [DOI: 10.1177/1747493020929948] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and hypothesis There is no consensus on the optimal endovascular management of the extracranial internal carotid artery steno-occlusive lesion in patients with acute ischemic stroke due to tandem occlusion. We hypothesized that intracranial mechanical thrombectomy plus emergent internal carotid artery stenting (and at least one antiplatelet therapy) is superior to intracranial mechanical thrombectomy alone in patients with acute tandem occlusion. Study design TITAN is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) study. Eligibility requires a diagnosis of acute ischemic stroke, pre-stroke modified Rankin Scale (mRS)≤2 (no upper age limit), National Institutes of Health Stroke Scale (NIHSS)≥6, Alberta Stroke Program Early Computed Tomography Score (ASPECTS)≥6, and tandem occlusion on the initial catheter angiogram. Tandem occlusion is defined as large vessel occlusion (intracranial internal carotid artery , M1 and/or M2 segment) and extracranial severe internal carotid artery stenosis ≥90% (NASCET) or complete occlusion. Patients are randomized in two balanced parallel groups (1:1) to receive either intracranial mechanical thrombectomy plus internal carotid artery stenting (and at least one antiplatelet therapy) or intracranial mechanical thrombectomy alone within 8 h of stroke onset. Up to 432 patients are randomized after tandem occlusion confirmation on angiogram. Study outcomes The primary outcome measure is complete reperfusion rate at the end of endovascular procedure, assessed as a modified Thrombolysis in Cerebral Infarction (mTICI) 3, and ≥4 point decrease in NIHSS at 24 h. Secondary outcomes include infarct growth, recurrent clinical ischemic event in the ipsilateral carotid territory, type and dose of antiplatelet therapy used, mRS at 90 (±15) days and 12 (±1) months. Safety outcomes are procedural complications, stent patency, intracerebral hemorrhage, and death. Economics analysis includes health-related quality of life, and costs utility comparison, especially with the need or not of endarterectomy. Discussion TITAN is the first randomized trial directly comparing two types of treatment in patients with acute ischemic stroke due to anterior circulation tandem occlusion, and especially assessing the safety and efficacy of emergent internal carotid artery stenting associated with at least one antiplatelet therapy in the acute phase of stroke reperfusion. Trial registration ClinicalTrials.gov NCT03978988
Collapse
Affiliation(s)
- François Zhu
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Gabriela Hossu
- CIC 1433, Technological Innovation, IADI, INSERM U1254, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Marc Soudant
- CIC 1433 Clinical Epidemiology, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Sébastien Richard
- CIC 1433 Plurithematic, Nancy University Hospital, Université de Lorraine, Nancy, France
- Department of Neurology, Stroke Unit, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Hamza Achit
- CIC 1433 Clinical Epidemiology, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Mélanie Beguinet
- CIC 1433 Clinical Epidemiology, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Vincent Costalat
- Department of Interventional Neuroradiology, CHRU Gui de Chauliac, Montpellier, France
| | | | - Arturo Consoli
- Department of Diagnostic and Interventional Neuroradiology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Bertrand Lapergue
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - Aymeric Rouchaud
- Department of Interventional Neuroradiology, CHU Dupuytren, Limoges, France
| | | | - Alessandra Biondi
- Department of Neuroradiology and Endovascular Therapy, Besançon University Hospital, Besancon, France
| | - Thierry Moulin
- Department of Neurology, Besançon University Hospital, Besancon, France
| | - Gaultier Marnat
- Department of Neuroradiology, University Hospital of Bordeaux, Bordeaux, France
| | - Igor Sibon
- Department of Neurology, Stroke Center, University Hospital of Bordeaux, Bordeaux, France
| | - Christophe Paya
- Department of Neuroradiology, Rennes University Hospital, Rennes, France
| | - Stéphane Vannier
- Department of Neurology, Rennes University Hospital, Rennes, France
| | - Christophe Cognard
- Department of Neuroradiology, Toulouse University Hospital, Toulouse, France
| | - Alain Viguier
- Department of Neurology, Toulouse University Hospital, Toulouse, France
| | - Mikael Mazighi
- Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France
| | - Michael Obadia
- Department of Neurology, Stroke Unit, Rothschild Foundation Hospital, Paris, France
| | - Wagih B Hassen
- Department of Neuroradiology, Saint-Anne Hospital, Paris, France
| | - Guillaume Turc
- Department of Neurology, Stroke Unit, Saint-Anne Hospital, Paris, France
| | | | - Yves Samson
- Department of Neurology, Stroke Unit, Pitié-Salpêtrière Hospital, Paris, France
| | | | - Cécile Preterre
- Department of Neurology, Nantes University Hospital, Nantes, France
| | - Charlotte Barbier
- Department of Neuroradiology, Caen University Hospital, Caen, France
| | | | - Kevin Janot
- Department of Neuroradiology, Tours University Hospital, Lille, France
| | - Mariam Annan
- Department of Neurology, Tours University Hospital, Lille, France
| | - Nicolas Bricout
- Department of Neuroradiology, Lille University Hospital, Lille, France
| | - Hilde Henon
- Department of Neurology, Lille University Hospital, Lille, France
| | - Sébastien Soize
- Department of Neuroradiology, Reims University Hospital, Lille, France
| | - Solène Moulin
- Department of Neurology, Reims University Hospital, Lille, France
| | | | - Peggy Reiner
- Department of Neurology, Lariboisière Hospital, Paris, France
| | - Raoul Pop
- Department of Neuroradiology, Strasbourg University Hospital, Strasbourg, France
| | - Valérie Wolff
- Department of Neurology, Stroke Unit, Strasbourg University Hospital, Strasbourg, France
| | - Julien Ognard
- Department of Neuroradiology, Brest University Hospital, Brest, France
| | - Serge Timsit
- Department of Neurology, Brest University Hospital, Brest, France
| | - Anthony Reyre
- Department of Neuroradiology, Marseille University Hospital, Marseille, France
| | - Charline Perot
- Department of Neurology, Marseille University Hospital, Marseille, France
| | | | | | - Serge Bracard
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
- CIC 1433, Technological Innovation, IADI, INSERM U1254, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - René Anxionnat
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
- CIC 1433, Technological Innovation, IADI, INSERM U1254, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Anne-Laure Derelle
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Romain Tonnelet
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Liang Liao
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
- CIC 1433, Technological Innovation, IADI, INSERM U1254, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Emmanuelle Schmitt
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Sophie Planel
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
| | - Francis Guillemin
- CIC 1433 Clinical Epidemiology, Nancy University Hospital, Université de Lorraine, Nancy, France
| | - Benjamin Gory
- Department of Diagnostic and Therapeutic Neuroradiology, Université de Lorraine, Nancy University Hospital, Nancy, France
- CIC 1433, Technological Innovation, IADI, INSERM U1254, Nancy University Hospital, Université de Lorraine, Nancy, France
| |
Collapse
|
35
|
Arnaud C, Boulanger M, Lorthioir A, Amar L, Azarine A, Azizi M, Boyer L, Chatelllier G, Jeunemaitre X, Mousseaux E, Oppenheim C, Thony F, Plouin PF, Persu A, Olin J, Touze E. Abstract 49: Male Sex is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia. Stroke 2020. [DOI: 10.1161/str.51.suppl_1.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Cervical artery dissection (CeAD) is one of the most frequent manifestations of fibromuscular dysplasia (FMD). However, the risk factors for CeAD are unknown. We investigated factors associated with CeAD in the ARCADIA (Assessment of Renal and Cervical Artery Dysplasia) registry and performed a pooled analysis of published and unpublished data.
Methods:
Patients included were women and men ≥18 years, diagnosed with renal, cervical, or intracranial artery FMD, prospectively recruited at 16 university hospitals in France and Belgium. Diagnosis of CeAD was established by stroke specialists in each participating center, according to standard diagnostic criteria. Associations between CeAD and potential determinants were assessed by calculations of crude and adjusted odds ratios.
Results:
Among 469 patients (415 women) with FMD, 68 (14.5%) had CeAD. CeAD patients were younger, more likely to be men and to have a history of migraine, and less likely to have a history of hypertension, than non-CeAD patients. In the multivariate analysis, male sex (OR=2.75 ; CI95% 1.39-5.46), history of migraine (OR=1.93 ; 1.08-3.44), age >50 years (OR=0.41 ; 0.23-0.74), history of hypertension (OR=0.35 ; 0.19-0.63), and the number of vascular beds involved by FMD >=3 (OR=2.46 ; 1.13-5.35) remained significantly associated with CeAD. We collected data from 2 published studies and unpublished data from the US and the European Registries. There was no overlap between studies. In a pooled analysis (289 CeAD in 1933 patients), male sex was significantly associated with CeAD (pooled OR=2.04 ; 1.41-2.95, I2=0%, Figure).
Conclusion:
In patients with FMD, male sex and multisite involvement are associated with of CeAD, in addition to other previous known risk factors.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Louis Boyer
- CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | - Jeffrey Olin
- Icahn Sch of Medicine at Mount Sinai, New York, NY
| | | |
Collapse
|
36
|
Touzé E, Southerland AM, Boulanger M, Labeyrie PE, Azizi M, Bouatia-Naji N, Debette S, Gornik HL, Hussain SM, Jeunemaitre X, Joux J, Kirton A, Le Hello C, Majersik JJ, Mocco J, Persu A, Sharma A, Worrall BB, Olin JW, Plouin PF. Fibromuscular Dysplasia and Its Neurologic Manifestations: A Systematic Review. JAMA Neurol 2019; 76:217-226. [PMID: 30285053 DOI: 10.1001/jamaneurol.2018.2848] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Importance Data on neurologic manifestations of fibromuscular dysplasia (FMD) are rare, and current knowledge remains limited. Objectives To present a comprehensive review of the epidemiologic characteristics, management, and prognosis of the neurologic manifestations associated with cerebrovascular FMD (ie, involving cervical or intracranial arteries) and to guide future research priorities. Evidence Review References were identified through searches of PubMed from inception to December 2017 using both the medical subject headings and text words. Additional sources were also identified by reviewing reference lists of relevant articles and through searches of the authors' personal files. Selected articles described at least 1 clinical or radiologic feature and/or outcome of cerebrovascular FMD. Isolated case reports could be included if they described interesting or noteworthy manifestations of FMD. Findings A total of 84 relevant references were identified. Diagnosis of cerebrovascular FMD is based on the appearance of alternating arterial dilatation and constriction ("string of beads") or of focal narrowing, with no sign of atherosclerotic or inflammatory lesions. Although the diagnosis is easily apparent on results of radiographic imaging, making a diagnosis can be challenging in children or individuals with atypical phenotypes, such as purely intracranial FMD and arterial diaphragm. Involvement of multiple arteries is common, and there is increased incidence of cervical artery dissection and intracranial aneurysms. A variant in the PHACTR1 gene has been associated with FMD as well as cervical artery dissection and migraine, although less than 5% of cases of FMD are familial. Headaches, mainly of the migraine type, are observed in up to 70% of patients with FMD. Cerebrovascular FMD is mostly asymptomatic, but the most frequent neurologic manifestations include transient ischemic attack and ischemic stroke, notably in the presence of associated cervical artery dissection. Other conditions associated with FMD include subarachnoid hemorrhage and, rarely, intracranial hemorrhage. Management relies on observational data and expert opinion. Antiplatelet therapy is considered reasonable to prevent thromboembolic complications. Endovascular therapy is typically restricted to cases with symptomatic stenosis despite optimal medical therapy or in those with rupture of an intracranial aneurysm. Conclusions and Relevance Longitudinal cohort studies of individuals of multiple ethnicities with biosampling are needed to better understand the risk factors, pathophysiological features, and outcomes of FMD. Patient advocacy groups could assist researchers in answering patient-centered questions regarding FMD.
Collapse
Affiliation(s)
- Emmanuel Touzé
- Normandie Université, Université Caen Normandie, Institut National de la Santé et de la Recherche Médicale U1237, Centre Hospitalier et Universitaire Caen, Caen, France
| | - Andrew M Southerland
- Department of Neurology, University of Virginia Health System, Charlottesville.,Department of Public Health Sciences, University of Virginia Health System, Charlottesville
| | - Marion Boulanger
- Normandie Université, Université Caen Normandie, Institut National de la Santé et de la Recherche Médicale U1237, Centre Hospitalier et Universitaire Caen, Caen, France
| | - Paul-Emile Labeyrie
- Normandie Université, Université Caen Normandie, Institut National de la Santé et de la Recherche Médicale U1237, Centre Hospitalier et Universitaire Caen, Caen, France.,Department of Radiology, University of Lyon, Hôpitaux de Lyon, Lyon, France
| | - Michel Azizi
- Paris-Descartes University, Institut National de la Santé et de la Recherche Médicale UMR970, Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
| | - Nabila Bouatia-Naji
- Paris-Descartes University, Institut National de la Santé et de la Recherche Médicale UMR970, Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
| | - Stéphanie Debette
- Department of Neurology, Memory Clinic, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France.,Institut National de la Santé et de la Recherche Médicale U1219, Bordeaux Population Health Research Center, Bordeaux, France
| | | | | | - Xavier Jeunemaitre
- Paris-Descartes University, Institut National de la Santé et de la Recherche Médicale UMR970, Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
| | - Julien Joux
- Department of Neurology, Centre Hospitalier et Universitaire Fort-de-France, Martinique, French West Indies
| | - Adam Kirton
- Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Claire Le Hello
- Normandie Université, Université Caen Normandie, Institut National de la Santé et de la Recherche Médicale U1237, Centre Hospitalier et Universitaire Caen, Caen, France.,Service de Médecine Vasculaire, Université de Saint-Etienne, Centre Hospitalier et Universitaire Saint-Etienne, Saint-Etienne, France
| | | | - J Mocco
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexandre Persu
- Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium.,Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Aditya Sharma
- Department of Medicine, University of Virginia Health System, Charlottesville
| | - Bradford B Worrall
- Department of Neurology, University of Virginia Health System, Charlottesville.,Department of Public Health Sciences, University of Virginia Health System, Charlottesville
| | - Jeffrey W Olin
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Pierre-François Plouin
- Paris-Descartes University, Institut National de la Santé et de la Recherche Médicale UMR970, Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
| |
Collapse
|
37
|
Boulanger M, Li L, Lyons S, Lovett N, Kubiak M, Silver L. Effect of Co-existing Vascular Disease on Long-term Risk of Recurrent Events after TIA or Stroke. J Vasc Surg 2019. [DOI: 10.1016/j.jvs.2019.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Boulanger M, Li L, Lyons S, Lovett NG, Kubiak MM, Silver L, Touzé E, Rothwell PM. Essen Risk Score in Prediction of Myocardial Infarction After Transient Ischemic Attack or Ischemic Stroke Without Prior Coronary Artery Disease. Stroke 2019; 50:3393-3399. [PMID: 31637970 PMCID: PMC7597993 DOI: 10.1161/strokeaha.119.025831] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose- More intensive secondary prevention with newer drugs may be cost-effective in patients with coronary artery disease (CAD). Whether some subgroups of patients who had a transient ischemic attack (TIA) or ischemic stroke, but no prior CAD are at similar high risk of myocardial infarction as those with prior CAD remains unclear. We determined whether the Essen score identified a subset of TIA/stroke patients without known prior CAD who, nevertheless, had a high risk of myocardial infarction on current secondary prevention management. Methods- In a population-based cohort (Oxford Vascular Study) of consecutive TIA or ischemic stroke patients recruited from 2002 to 2014, 10-year actuarial risks of myocardial infarction and of recurrent ischemic stroke were determined by face-to-face follow-up in patients with and without prior CAD using Kaplan-Meier analyses. Predictive value of the Essen score was assessed with C statistic. Results- Of 2555 patients with TIA/stroke (13 070 patient-years of follow-up), 10-year risk of myocardial infarction in those without prior CAD (n=2017, 78.9%) ranged from 0.9% (95% CI, 0-1.9) at Essen score ≤1 to 29.8% (95% CI, 7.7-46.6) in those with a score ≥5 (C statistic =0.64 [95% CI, 0.57-0.71]; P<0.001). The score tended to be less predictive (difference: P=0.0460) for the risk of recurrent ischemic stroke (C statistic =0.57 [95% CI, 0.54-0.60]). Compared with patients with prior CAD (n=538, 21.1%), an Essen risk score of ≥4 (n=294, 11.5%) in those without prior CAD identified a subgroup at similar high 10-year risks of myocardial infarction (17.2% [95% CI, 6.9-26.3] versus 16.9% [95% CI, 11.5-22.0]) and of recurrent stroke (40.4% [95% CI, 26.7-51.6] versus 32.4% [95% CI, 25.2-38.8]). Conclusions- The Essen score is a simple clinical score to risk-stratify patients with TIA/stroke without prior CAD and to identify subsets who may be at sufficiently high risk of myocardial infarction and recurrent stroke to justify more intensive treatment or inclusion in trials.
Collapse
Affiliation(s)
- Marion Boulanger
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.).,Normandie Université, UNICAEN, CHU Caen Normandie, Service de Neurologie, INSERM U1237, avenue de la Côte de Nacre, Caen, France (M.B., E.T.)
| | - Linxin Li
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| | - Shane Lyons
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| | - Nicola G Lovett
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| | - Magdalena M Kubiak
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| | - Louise Silver
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| | - Emmanuel Touzé
- Normandie Université, UNICAEN, CHU Caen Normandie, Service de Neurologie, INSERM U1237, avenue de la Côte de Nacre, Caen, France (M.B., E.T.)
| | - Peter M Rothwell
- From the Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.)
| |
Collapse
|
39
|
Boulanger M, Li L, Lyons S, Lovett NG, Kubiak MM, Silver L, Touzé E, Rothwell PM. Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke. Neurology 2019; 93:e695-e707. [PMID: 31337715 PMCID: PMC6715511 DOI: 10.1212/wnl.0000000000007935] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 03/21/2019] [Indexed: 01/24/2023] Open
Abstract
OBJECTIVE To determine whether patients with TIA or ischemic stroke with coexisting cardiovascular disease (i.e., history of coronary or peripheral artery disease) are still at high risk of recurrent ischemic events despite current secondary prevention guidelines. METHODS In a population-based study in Oxfordshire, UK (Oxford Vascular Study), we studied consecutive patients with TIA or ischemic stroke for 2002-2014. Patients were treated according to current secondary prevention guidelines and we determined risks of coronary events, recurrent ischemic stroke, and major bleeding stratified by the presence of coexisting cardiovascular disease. RESULTS Among 2,555 patients (9,148 patient-years of follow-up), those (n = 640; 25.0%) with coexisting cardiovascular disease (449 coronary only; 103 peripheral only; 88 both) were at higher 10-year risk of coronary events than those without (22.8%, 95% confidence interval 17.4-27.9; vs 7.1%, 5.3-8.8; p < 0.001; age- and sex-adjusted hazard ratio [HR] 3.07, 2.24-4.21) and of recurrent ischemic stroke (31.5%, 25.1-37.4; vs 23.4%, 20.5-26.2; p = 0.0049; age- and sex-adjusted HR 1.23, 0.99-1.53), despite similar rates of use of antithrombotic and lipid-lowering medication. However, in patients with noncardioembolic TIA/stroke, risk of extracranial bleeds was also higher in those with coexisting cardiovascular disease, particularly in patients aged <75 years (8.1%, 2.8-13.0; vs 3.4%, 1.6-5.3; p = 0.0050; age- and sex-adjusted HR 2.71, 1.16-6.30), although risk of intracerebral hemorrhage was not increased (age- and sex-adjusted HR 0.36, 0.04-2.99). CONCLUSIONS As in older studies, patients with TIA/stroke with coexisting cardiovascular disease remain at high risk of recurrent ischemic events despite current management. More intensive lipid-lowering might therefore be justified, but benefit from increased antithrombotic treatment might be offset by the higher risk of extracranial bleeding.
Collapse
Affiliation(s)
- Marion Boulanger
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Linxin Li
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Shane Lyons
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Nicola G Lovett
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Magdalena M Kubiak
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Louise Silver
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Emmanuel Touzé
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France
| | - Peter M Rothwell
- From the Centre for Prevention of Stroke and Dementia (M.B., L.L., S.L., N.G.L., M.M.K., L.S., P.M.R.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, UK; and Service de Neurologie (M.B., E.T.), CHU Caen Normandie, UNICAEN, Normandie Université, INSERM U1237, Caen, France.
| |
Collapse
|
40
|
Boulanger M, Coenen R, Boemer F, Deberg M, Debois D, Bosseloir A. WS16-4 Newborn screening of cystic fibrosis: analytical and clinical assessment of a new commercial kit for PAP quantification. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30214-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Boulanger M, Lapergue B, Turjman F, Touzé E, Anxionnat R, Bracard S, Piotin M, Gory B. First-line contact aspiration vs stent-retriever thrombectomy in acute ischemic stroke patients with large-artery occlusion in the anterior circulation: Systematic review and meta-analysis. Interv Neuroradiol 2019; 25:244-253. [PMID: 30864466 DOI: 10.1177/1591019918821074] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND In acute ischemic stroke patients with large-artery occlusion, uncertainties remain about whether clinically important outcomes are comparable between first-line contact aspiration and stent-retriever thrombectomy, although two trials have investigated whether one strategy should be preferred over another. PURPOSE The purpose of this article is to compare the efficacy and safety of first-line contact aspiration and stent-retriever thrombectomy in stroke patients with anterior circulation large-artery occlusion. METHODS We undertook a systematic review of studies of patients treated for large-artery occlusion, with the latest devices of either strategy, within six hours of stroke onset. We determined rates of final complete reperfusion (defined as modified Thrombolysis In Cerebral Infarction score = 3), periprocedural complications and 90-day functional independence (defined as modified Rankin Scale (mRS) score 0-2), and excellent outcome (defined as mRS score 0-1) after contact aspiration and after stent-retriever thrombectomy using random-effects meta-analyses. Any differential effects in rates between the two strategies were assessed using random-effects meta-regressions. RESULTS Fifteen studies (1817 patients) were included. There was no difference in rates of final complete reperfusion at the end of all endovascular procedures between contact aspiration and stent retrievers (51.1%, 95% confidence interval (CI) 39.3-62.9; vs 38.3%, 95% CI 28.6-48.0; pint = 0.14), 90-day functional independence (45.0%, 40.7-49.2; vs 52.4%, 47.7-57.1; pint = 0.45) and excellent outcome (32.1%, 25.7-38.5; vs 34.1%, 21.2-46.9; pint = 0.94). Rates of periprocedural complications did not differ between the two strategies. CONCLUSIONS Current data suggest no difference in efficacy and safety between first-line contact aspiration and stent-retriever thrombectomy in stroke patients with large-artery occlusion.
Collapse
Affiliation(s)
- Marion Boulanger
- 1 Normandie University, UNICAEN, Inserm U1237, CHU Caen, Stroke Unit, Caen, France
| | - Bertrand Lapergue
- 2 Department of Neurology, Foch Hospital, University Versailles Saint-Quentin en Yvelines, Suresnes, France
| | - Francis Turjman
- 3 Department of Interventional Neuroradiology, Hospices Civils de Lyon, Lyon, France
| | - Emmanuel Touzé
- 1 Normandie University, UNICAEN, Inserm U1237, CHU Caen, Stroke Unit, Caen, France
| | - René Anxionnat
- 4 Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Nancy, Nancy, France.,5 University of Lorraine, INSERM U1254, IADI, F-54000, Nancy, France
| | - Serge Bracard
- 4 Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Nancy, Nancy, France.,5 University of Lorraine, INSERM U1254, IADI, F-54000, Nancy, France
| | - Michel Piotin
- 6 Department of Interventional Neuroradiology, Rothschild Foundation, Paris, France
| | - Benjamin Gory
- 4 Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Nancy, Nancy, France.,5 University of Lorraine, INSERM U1254, IADI, F-54000, Nancy, France
| |
Collapse
|
42
|
Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, Kadian-Dodov D, Kim ESH, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touzé E, van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 2019; 24:164-189. [DOI: 10.1177/1358863x18821816] [Citation(s) in RCA: 151] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
This article is a comprehensive document on the diagnosis and management of fibromuscular dysplasia (FMD), which was commissioned by the working group ‘Hypertension and the Kidney’ of the European Society of Hypertension (ESH) and the Society for Vascular Medicine (SVM). This document updates previous consensus documents/scientific statements on FMD published in 2014 with full harmonization of the position of European and US experts. In addition to practical consensus-based clinical recommendations, including a consensus protocol for catheter-based angiography and percutaneous angioplasty for renal FMD, the document also includes the first analysis of the European/International FMD Registry and provides updated data from the US Registry for FMD. Finally, it provides insights on ongoing research programs and proposes future research directions for understanding this multifaceted arterial disease.
Collapse
Affiliation(s)
- Heather L Gornik
- Division of Cardiovascular Medicine, University Hospitals Cleveland Medical Center and UH Harrington Heart and Vascular Institute, Cleveland, OH, USA
| | - Alexandre Persu
- Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - David Adlam
- Department of Cardiovascular Sciences, Glenfield Hospital, Leicester, UK
- NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
| | - Lucas S Aparicio
- Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Michel Azizi
- Paris Descartes University, Paris, France
- Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
- Institut national de la santé et de la recherche médicale, Centre d’Investigation Clinique 1418, Paris, France
| | - Marion Boulanger
- Normandie Université, UNICAEN, Inserm U1237, CHU Caen Normandie, Caen, France
| | - Rosa Maria Bruno
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Peter de Leeuw
- Department of Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Natalia Fendrikova-Mahlay
- Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA
| | - James Froehlich
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA
| | - Santhi K Ganesh
- Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA
| | - Bruce H Gray
- University of South Carolina School of Medicine/Greenville, Greenville, SC, USA
| | - Cathlin Jamison
- Association belge de patients atteints de Dysplasie Fibromusculaire/FMD Groep België (FMD-Be), Brussels, Belgium
| | | | - Xavier Jeunemaitre
- APHP, Department of Genetics and Centre for Rare Vascular Diseases, Hôpital Européen Georges Pompidou, Paris, France
- INSERM, U970 – PARCC, University Paris Descartes, Sorbonne Paris
Cité, Paris, France
| | - Daniella Kadian-Dodov
- Zena and Michael A Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health; Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther SH Kim
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Jason C Kovacic
- Zena and Michael A Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health; Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Pamela Mace
- Fibromuscular Dysplasia Society of America (FMDSA), North Olmsted, OH, USA
| | - Alberto Morganti
- Centro Fisiologia Clinica e Ipertensione, Policlinico Hospital, University of Milan, Milan, Italy
| | - Aditya Sharma
- Department of Medicine, Cardiovascular Medicine Division, University of Virginia, Charlottesville, VA, USA
| | | | - Emmanuel Touzé
- Normandie Université, UNICAEN, Inserm U1237, CHU Caen Normandie, Caen, France
| | - Patricia van der Niepen
- Department of Nephrology & Hypertension Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
| | - Jiguang Wang
- Shanghai Institute of Hypertension and Center for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Ido Weinberg
- Vascular Medicine Section and Vascular Center, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Scott Wilson
- Monash University (Central Clinical School of Medicine), Melbourne, VIC, Australia
- Department of Renal Medicine, Alfred Health, Melbourne, VIC, Australia
| | - Jeffrey W Olin
- Zena and Michael A Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health; Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Pierre-Francois Plouin
- Paris Descartes University, Paris, France
- Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France
- Institut national de la santé et de la recherche médicale, Centre d’Investigation Clinique 1418, Paris, France
| |
Collapse
|
43
|
Boulanger M, Schneckenburger R, Join-Lambert C, Werring DJ, Wilson D, Hodel J, Zuber M, Touzé E. Diffusion-Weighted Imaging Hyperintensities in Subtypes of Acute Intracerebral Hemorrhage: Meta-Analysis. Stroke 2019; 50:135-142. [PMID: 30580720 DOI: 10.1161/strokeaha.118.021407] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose- Diffusion-weighted imaging (DWI) hyperintensities in intracerebral hemorrhage (ICH) are associated with increased risk of recurrent ICH, cognitive impairment, and death, but whether these lesions are specific to a subtype of ICH remains uncertain. We investigated the association between DWI lesions and ICH subtype and explored the risk factors for DWI lesions. Methods- In a systematic review of ICH studies, we identified those reporting prevalence of DWI lesions. Two reviewers independently assessed study eligibility and risk of bias and collected data. We determined the pooled prevalence of DWI lesions within 90 days after ICH onset for cerebral amyloid angiopathy- and hypertensive angiopathy-related ICH using random-effects meta-analysis. We calculated odds ratios to compare prevalence of DWI lesions by ICH subtype and to assess risk factors for DWI lesions. Results- Eleven studies (1910 patients) were included. The pooled prevalence of DWI lesions was 18.9% (95% CI, 11.1-26.7) in cerebral amyloid angiopathy- and 21.0% (95% CI, 15.3-26.6) in hypertensive angiopathy-related ICH. There was no difference in the prevalence of DWI lesions between cerebral amyloid angiopathy- (64/292 [21.9%]) and hypertensive angiopathy-related ICH (79/370 [21.4%]; odds ratio, 1.25; 95% CI, 0.73-2.15) in the 5 studies reporting data on both ICH pathogeneses. In all ICH, presence of DWI lesions was associated with neuroimaging features of microangiopathy (leukoaraiosis extension, previous ICH, and presence, and number of microbleeds) but not with vascular risk factors or the use of antithrombotic therapies. Conclusions- Prevalence of DWI lesions in acute ICH averages 20%, with no difference between cerebral amyloid angiopathy- and hypertensive angiopathy-related ICH. Detection of DWI lesions may add valuable information to assess the progression of the underlying microangiopathy.
Collapse
Affiliation(s)
- Marion Boulanger
- From the Normandie University, UNICAEN, Inserm U1237, Caen, France (M.B., M.Z., E.T.)
- CHU Côte de Nacre, Neurology Department, Caen, France (M.B., R.S., E.T.)
| | | | - Claire Join-Lambert
- Neurology Department, Hôpital Saint Joseph, Université Paris Descartes, France (C.J.-L., M.Z.)
| | - David J Werring
- Department of Brain Repair and Rehabilitation, Stroke Research Centre, Institute of Neurology, Queen Square, London, United Kingdom (D.J.W., D.W.)
| | - Duncan Wilson
- Department of Brain Repair and Rehabilitation, Stroke Research Centre, Institute of Neurology, Queen Square, London, United Kingdom (D.J.W., D.W.)
| | - Jérome Hodel
- Neuroradiology Department, Hôpital Henri Mondor, Université Paris-Est Créteil, France (J.H.)
| | - Mathieu Zuber
- From the Normandie University, UNICAEN, Inserm U1237, Caen, France (M.B., M.Z., E.T.)
- Neurology Department, Hôpital Saint Joseph, Université Paris Descartes, France (C.J.-L., M.Z.)
| | - Emmanuel Touzé
- From the Normandie University, UNICAEN, Inserm U1237, Caen, France (M.B., M.Z., E.T.)
- CHU Côte de Nacre, Neurology Department, Caen, France (M.B., R.S., E.T.)
| |
Collapse
|
44
|
Tsivgoulis G, Wilson D, Katsanos AH, Sargento-Freitas J, Marques-Matos C, Azevedo E, Adachi T, von der Brelie C, Aizawa Y, Abe H, Tomita H, Okumura K, Hagii J, Seiffge DJ, Lioutas VA, Traenka C, Varelas P, Basir G, Krogias C, Purrucker JC, Sharma VK, Rizos T, Mikulik R, Sobowale OA, Barlinn K, Sallinen H, Goyal N, Yeh SJ, Karapanayiotides T, Wu TY, Vadikolias K, Ferrigno M, Hadjigeorgiou G, Houben R, Giannopoulos S, Schreuder FHBM, Chang JJ, Perry LA, Mehdorn M, Marto JP, Pinho J, Tanaka J, Boulanger M, Al-Shahi Salman R, Jäger HR, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A, Mitsias PD, Alexandrov AV, Ambler G, Werring DJ. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol 2018; 84:694-704. [PMID: 30255970 DOI: 10.1002/ana.25342] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Revised: 09/13/2018] [Accepted: 09/14/2018] [Indexed: 01/11/2023]
Abstract
OBJECTIVE Whether intracerebral hemorrhage (ICH) associated with non-vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain. METHODS We performed a systematic review and individual patient data meta-analysis of cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes were assessed in multivariate regression analyses adjusted for age, sex, ICH location, and intraventricular hemorrhage extension. RESULTS We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age = 77 years, 52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs 26.5%; hazard ratio = 0.94, 95% confidence interval [CI] = 0.67-1.31). However, in multivariate analyses adjusting for potential confounders, NOAC-ICH was associated with lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression coefficient = -2.83, 95% CI = -5.28 to -0.38), lower likelihood of severe stroke (NIHSS > 10 points) on admission (odds ratio [OR] = 0.50, 95% CI = 0.30-0.84), and smaller baseline hematoma volume (linear regression coefficient = -0.24, 95% CI = -0.47 to -0.16). The two groups did not differ in the likelihood of baseline hematoma volume < 30cm3 (OR = 1.14, 95% CI = 0.81-1.62), hematoma expansion (OR = 0.97, 95% CI = 0.63-1.48), in-hospital mortality (OR = 0.73, 95% CI = 0.49-1.11), functional status at discharge (common OR = 0.78, 95% CI = 0.57-1.07), or functional status at 3 months (common OR = 1.03, 95% CI = 0.75-1.43). INTERPRETATION Although functional outcome at discharge, 1 month, or 3 months was comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline hematoma volumes and less severe acute stroke syndromes. Ann Neurol 2018;84:702-712.
Collapse
Affiliation(s)
- Georgios Tsivgoulis
- Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.,Department of Neurology, University of Tennessee Health Science Center, Memphis, TN
| | - Duncan Wilson
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom, New Zealand Brain Research Institute, Christchurch, New Zealand
| | - Aristeidis H Katsanos
- Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.,Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece
| | - João Sargento-Freitas
- Department of Neurology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.,Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Cláudia Marques-Matos
- Department of Neurology, São João University Hospital Center, Porto, Portugal.,Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal
| | - Elsa Azevedo
- Department of Neurology, São João University Hospital Center, Porto, Portugal.,Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal
| | - Tomohide Adachi
- Department of Neurology and General Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| | | | - Yoshifusa Aizawa
- Department of Research and Development, Tachikawa Medical Center, Nagaoka, Japan
| | - Hiroshi Abe
- Department of Research and Development, Tachikawa Medical Center, Nagaoka, Japan
| | - Hirofumi Tomita
- Department of Cardiology and Department of Hypertension and Stroke Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Ken Okumura
- Advanced Arrhythmia Therapeutic Branch, Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan
| | - Joji Hagii
- Hirosaki Stroke and Rehabilitation Center, Hirosaki, Japan
| | - David J Seiffge
- Stroke Center and Neurology, University Hospital and University of Basel, Basel, Switzerland
| | | | - Christopher Traenka
- Stroke Center and Neurology, University Hospital and University of Basel, Basel, Switzerland
| | | | - Ghazala Basir
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada
| | - Christos Krogias
- Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
| | - Jan C Purrucker
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - Vijay K Sharma
- Division of Neurology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Timolaos Rizos
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - Robert Mikulik
- International Clinical Research Center and Neurology Department, St Anne's Hospital and Masaryk University, Brno, Czech Republic
| | - Oluwaseun A Sobowale
- Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
| | - Kristian Barlinn
- Department of Neurology, Dresden Neurovascular Center, Dresden, Germany
| | - Hanne Sallinen
- Department of Neurology, Helsinki University Hospital, Helsinki, Finland
| | - Nitin Goyal
- Department of Neurology, University of Tennessee Health Science Center, Memphis, TN
| | - Shin-Joe Yeh
- Stroke Center and Department of Neurology, National Taiwan University Hospital, Taiwan
| | - Theodore Karapanayiotides
- Second Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Teddy Y Wu
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | | | - Marc Ferrigno
- Department of Neurology, Lille University, INSERM U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Lille, France
| | | | - Rik Houben
- Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Sotirios Giannopoulos
- Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece
| | - Floris H B M Schreuder
- Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.,Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Jason J Chang
- Department of Neurology, University of Tennessee Health Science Center, Memphis, TN
| | - Luke A Perry
- Department of Neurosciences, Eastern Health, Melbourne, Victoria, Australia
| | - Maximilian Mehdorn
- Department of Neurosurgery, Georg August University of Göttingen, Göttingen, Germany
| | - João-Pedro Marto
- Neurology Department, Egas Moniz Hospital, West Lisbon Hospital Center, Lisbon, Portugal.,CEDOC, Nova Medical School, New University of Lisbon, Lisbon, Portugal
| | - João Pinho
- Department of Neurology, Braga Hospital, Braga, Portugal
| | - Jun Tanaka
- Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Marion Boulanger
- Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Rustam Al-Shahi Salman
- Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Hans R Jäger
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, United Kingdom
| | - Clare Shakeshaft
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom, New Zealand Brain Research Institute, Christchurch, New Zealand
| | - Yusuke Yakushiji
- Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
| | - Philip M C Choi
- Department of Neurosciences, Eastern Health, Melbourne, Victoria, Australia
| | - Julie Staals
- Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Charlotte Cordonnier
- Department of Neurology, Lille University, INSERM U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Lille, France
| | - Jiann-Shing Jeng
- Stroke Center and Department of Neurology, National Taiwan University Hospital, Taiwan
| | - Roland Veltkamp
- Division of Brain Sciences, Department of Stroke Medicine, Imperial College London, United Kingdom
| | - Dar Dowlatshahi
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada
| | - Stefan T Engelter
- Stroke Center and Neurology, University Hospital and University of Basel, Basel, Switzerland.,Neurorehabilitation Unit, University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland
| | - Adrian R Parry-Jones
- Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
| | - Atte Meretoja
- Department of Neurology, Helsinki University Hospital, Helsinki, Finland.,Department of Medicine and Neurology at Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
| | - Panayiotis D Mitsias
- Department of Neurology, Henry Ford Hospital, Detroit, MI.,Department of Neurology, School of Medicine, University of Crete, Crete, Greece
| | - Andrei V Alexandrov
- Department of Neurology, University of Tennessee Health Science Center, Memphis, TN
| | - Gareth Ambler
- Department of Statistical Science, University College London, London, United Kingdom
| | - David J Werring
- Stroke Research Centre, Department of Brain Repair and Rehabilitation, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom, New Zealand Brain Research Institute, Christchurch, New Zealand
| |
Collapse
|
45
|
Devillers R, Bourgeois R, Perrot N, Boulanger M, Rosa M, Bossé Y, Thériault S, Pibarot P, Arsenault B, Mathieu P. AUTOTAXIN CARRIED BY LP(A): A NEW BIOMARKER OF THE CALCIFIC AORTIC VALVE STENOSIS. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
46
|
Piel C, Pouchieu C, Tual S, Migault L, Lemarchand C, Carles C, Boulanger M, Gruber A, Rondeau V, Marcotullio E, Lebailly P, Baldi I. Tumeurs du système nerveux central et expositions agricoles dans la cohorte AGRICAN. ARCH MAL PROF ENVIRO 2018. [DOI: 10.1016/j.admp.2018.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Boulanger M, Béjot Y, Rothwell PM, Touzé E. Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-Analysis. J Am Heart Assoc 2018; 7:e007267. [PMID: 29348322 PMCID: PMC5850155 DOI: 10.1161/jaha.117.007267] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 11/17/2017] [Indexed: 11/25/2022]
Abstract
BACKGROUND Uncertainties remain about the current risk of myocardial infarction (MI) after ischemic stroke or transient ischemic attack. METHODS AND RESULTS We undertook a systematic review to estimate the long-term risk of MI, compared to recurrent stroke, with temporal trends in ischemic stroke/transient ischemic attack patients. Annual risks and 95% confidence intervals (95% CI) of MI and recurrent stroke were estimated using random-effect meta-analyses. We calculated incidence ratios of MI/recurrent stroke, for fatal and nonfatal events, using similar analyses. Rate ratios for MI in patients with potential risk factors compared to those without were calculated using Poisson regression.A total of 58 studies (131 299 patients) with a mean (range) follow-up of 3.5 (1.0-10.0) years were included. The risk of MI was 1.67%/y (95% CI 1.36-1.98, Phet<0.001 for heterogeneity) and decreased over time (Pint=0.021); 96% of the heterogeneity between studies was explained by study design, study period, follow-up duration, mean age, proportion of patients on antithrombotic therapy, and incident versus combined ischemic stroke/transient ischemic attack. The risk of recurrent stroke was 4.26%/y (95% CI 3.43-5.09, Phet<0.001), with no change over time (Pint=0.63). The risk of fatal MI was half the risk of recurrent strokes ending in fatality (incidence ratio=0.51, 95% CI 0.14-0.89, Phet=0.58). The risk of nonfatal MI was 75% smaller than the risk of recurrent nonfatal stroke (incidence ratio=0.25, 95%CI 0.02-0.50, Phet=0.68). Male sex, hypertension, coronary and peripheral artery diseases were associated with a doubled risk of MI. CONCLUSIONS After ischemic stroke/transient ischemic attack, the risk of MI is currently <2%/y, and recurrent stroke is a more common cause of death than MI.
Collapse
Affiliation(s)
- Marion Boulanger
- Normandie Université UNICAEN, Inserm U1237 CHU Caen, Caen, France
- Stroke Prevention Research Unit, University Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, United Kingdom
| | - Yannick Béjot
- Department of Neurology, Dijon Stroke Registry, Pathophysiology and Epidemiology of Cerebro-Cardiovascular Diseases (PEC2) Team, EA7460, CHU Dijon, University of Burgundy, Dijon, France
| | - Peter M Rothwell
- Stroke Prevention Research Unit, University Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, United Kingdom
| | - Emmanuel Touzé
- Normandie Université UNICAEN, Inserm U1237 CHU Caen, Caen, France
| |
Collapse
|
48
|
Bouchard M, Marsit O, Clavel M, Clisson M, Drolet M, Arsenault M, Couet J, Boulanger M, Mathieu P, Pibarot P, Beaudoin J. USE OF CARDIAC MAGNETIC RESONANCE TO IDENTIFY MITRAL VALVE FIBROTIC CHANGES AFTER MYOCARDIAL INFARCTION: VALIDATION IN A LARGE ANIMAL MODEL. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Boulanger M, Al-Shahi Salman R, Kerssens J, Wild SH. Association between diabetes mellitus and incidence of intracerebral haemorrhage and case fatality rates: A retrospective population-based cohort study. Diabetes Obes Metab 2017; 19:1193-1197. [PMID: 28296194 DOI: 10.1111/dom.12934] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 03/02/2017] [Accepted: 03/06/2017] [Indexed: 12/01/2022]
Abstract
We investigated the associations between diabetes (type 1, type 2 or no diabetes) and intracerebral haemorrhage (ICH) incidence as well as case fatality after ICH, in a retrospective cohort study of people aged 40 to 89 years in Scotland during the period 2004 to 2013, using linkage of population-based records of diagnosed diabetes, hospital discharges and deaths. We calculated ICH incidence and 30-day case fatality after hospital admission for ICH, along with their relative risks (RR) and 95% confidence intervals (CIs), among people with type 1 or type 2 diabetes compared to people without diabetes, adjusting for age, sex and socio-economic status (SES). There were 77, 1275 and 9778 incident ICH events and the case-fatality rate was 44% (95% CI 33, 57), 38% (95% CI 35, 41) and 36% (95% CI 35, 37) in people with type 1, type 2 and without diabetes, respectively. In comparison with absence of diabetes, type 1 diabetes was associated with a higher incidence of ICH (1.74, 95% CI 1.38-2.21) and higher case fatality after ICH (1.35, 95% CI 1.01-1.70), after adjustment for age, sex and SES. The small increases in ICH incidence (1.06, 95% CI 0.99-1.12) and case-fatality (1.04, 95% CI 0.96-1.13) in people with type 2 diabetes compared with people without diabetes were not statistically significant.
Collapse
Affiliation(s)
- Marion Boulanger
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- Normandy University, UNICAEN, CHU Côte de Nacre, Neurology Service, Caen, France
| | | | - Jan Kerssens
- Information Services Division, NHS National Services Scotland, Edinburgh, UK
| | - Sarah H Wild
- Usher Institute for Population Health Sciences and Informatics, Medical School, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
50
|
Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, Sobowale OA, Sallinen H, Yeh SJ, Wu TY, Ferrigno M, Houben R, Schreuder FHBM, Perry LA, Tanaka J, Boulanger M, Al-Shahi Salman R, Jäger HR, Ambler G, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A, Werring DJ. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 2017; 88:1693-1700. [PMID: 28381513 PMCID: PMC5409844 DOI: 10.1212/wnl.0000000000003886] [Citation(s) in RCA: 111] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Accepted: 01/18/2017] [Indexed: 11/15/2022] Open
Abstract
Objective: In an international collaborative multicenter pooled analysis, we compared mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE) between non–vitamin K antagonist oral anticoagulation–related ICH (NOAC-ICH) and vitamin K antagonist–associated ICH (VKA-ICH). Methods: We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We addressed heterogeneity using a shared frailty term. Good functional outcome was defined as discharge modified Rankin Scale score ≤2 and investigated in multivariable logistic regression. ICH volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an ICH volume increase >33% or >6 mL from baseline within 72 hours. Results: We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume was 14.4 mL (interquartile range [IQR] 3.6–38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0–27.9) for VKA-ICH (p = 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [p = 0.64]; adjusted Cox hazard ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52–1.64] [p = 0.79]), the rate of HE (NOAC-ICH n = 29/48 [40%] vs VKA-ICH n = 93/140 [34%] [p = 0.45]), or functional outcome at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95% CI 0.18–1.19 [p = 0.11]). Conclusions: In our international collaborative multicenter pooled analysis, baseline ICH volume, hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-ICH and VKA-ICH.
Collapse
Affiliation(s)
- Duncan Wilson
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - David J Seiffge
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Christopher Traenka
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Ghazala Basir
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Jan C Purrucker
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Timolaos Rizos
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Oluwaseun A Sobowale
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Hanne Sallinen
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Shin-Joe Yeh
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Teddy Y Wu
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Marc Ferrigno
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Rik Houben
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Floris H B M Schreuder
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Luke A Perry
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Jun Tanaka
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Marion Boulanger
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Rustam Al-Shahi Salman
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Hans R Jäger
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Gareth Ambler
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Clare Shakeshaft
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Yusuke Yakushiji
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Philip M C Choi
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Julie Staals
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Charlotte Cordonnier
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Jiann-Shing Jeng
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Roland Veltkamp
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Dar Dowlatshahi
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Stefan T Engelter
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Adrian R Parry-Jones
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - Atte Meretoja
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland
| | - David J Werring
- From the Stroke Research Center (D.W., C.S., D.J.W.) and Neuroradiological Academic Unit (H.R.J.), Department of Brain Repair and Rehabilitation, Institute of Neurology, and Department of Statistical Science (G.A.), UCL, London, UK; Stroke Center and Neurology (D.J.S., C.T., S.T.E.), University Hospital Basel, University of Basel, Switzerland; Ottawa Hospital Research Institute and University of Ottawa (G.B., D.D.), Canada; Department of Neurology (J.C.P., T.R.), Heidelberg University Hospital, Germany; Manchester Academic Health Sciences Center (O.A.S., A.R.P.-J.), Salford Royal NHS Foundation Trust, UK; Department of Neurology (H.S., A.M.), Helsinki University Hospital, Finland; Stroke Center & Department of Neurology (S.-J.Y., J.-S.J.), Department of Neurology, National Taiwan University Hospital, Taipei; Department of Medicine and neurology at the Royal Melbourne Hospital (T.Y.W., A.M.), University of Melbourne, Parkville, Australia; U1171-Degenerative & Vascular Cognitive Disorders (M.F., C.C.), Univ Lille, Inserm, CHU Lille, France; Department of Neurology (R.H., F.H.B.M.S., J.S.), Maastricht University Medical Center, the Netherlands; Department of Neurosciences (J.A.P., P.M.C.C.), Eastern Health, Melbourne, Australia; Division of Neurology, Department of Internal Medicine (J.T., Y.Y.), Saga University Faculty of Medicine, Japan; Division of Clinical Neurosciences (M.B., R.A.-S.S.), Center for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh; Department of Stroke Medicine, Division of Brain Sciences (R.V.), Imperial College London, UK; and Neurorehabilitation Unit (S.T.E.), University of Basel and University Center for Medicine of Aging, Felix Platter Hospital, Switzerland.
| | | |
Collapse
|